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“Research is the art of seeing what everyone else 
has seen, and doing what no-one else has done.” 
Anonymous 
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Zusammenfassung 
Der Hepatozyten-Wachstumsfaktor (HGF/SF) ist ein im gesamten Organismus 
vorkommendes Molekül und besitzt mitose-, motilitäts-, angiogenese-, und trans-
formationsfördernde Funktionen. Der Rezeptor für HGF/SF ist das Protein c-Met, 
welches durch das Proto-Oncogen c-met codiert wird. c-Met und/oder HGF/SF werden 
in vielen Tumoren übermäßig produziert, wodurch die Tumore hochsensitiv für HGF/SF-
vermittelte Signale werden. Eine erhöhe Inzidenz bösartiger Neubildungen und post-
operatives Wachstum von einzelnen Residualtumorzellen kann im Hepatoblastom (HB) 
und hepatozellulärem Karzinom (HCC) beobachtet werden, wenn der Serumspiegel von 
HGF/SF signifikant erhöht ist. Obwohl diese beiden Tumore zwei unterschiedliche 
Subtypen von Leberepithelialtumoren darstellen und sich deshalb hinsichtlich ihrer 
histologischen und klinischen Charakteristika deutlich voneinander unterscheiden, kann 
eine vergleichende Analyse der Auswirkungen von HGF/SF möglicherweise 
Aufschlüsse über die onkologischen Signalwege geben, die schließlich zur 
Tumorprogression führen. Die Ergebnisse dieser Studie zeigen, dass HGF/SF die 
Überlebensrate von Tumorzellen nach Induktion der Apoptose durch Cisplatin und 
Camptothecin, sowie Serumdepletion in einer Phosphoinositol 3-Kinase (PI3K)-
abhängigen Weise positiv begünstigt. Weiterhin konnten Unterschiede in der HGF/SF-
Sensitivität zwischen HB- und HCC-Zellen festgestellt werden, die auf unterschiedliche 
c-Met Expression zurückzuführen ist. Dadurch wird deutlich, dass HGF/SF zum 
Überleben von Tumorzellen beiträgt und damit die Tumorprogression fördert. 
Ausserdem konnte in dieser Studie HGF/SF als wesentlicher Faktor für eine erhöhte 
HB- und HCC-Zellmobilität identifiziert werden. HGF/SF induziert die Tumorzell-
wanderung, die durch eine vermehrte ‚Snail’-Produktion erreicht wird. Snail ist ein 
Transkriptionsrepressor, der eine entscheidende Rolle in der Epithelial-Mesenchymalen 
Transition (EMT) spielt. Snail reprimiert u.a. die Expression der E-cadherin und 
Claudin-3 Gene und ist für die HGF/SF-induzierte Zelldispersion essentiell. 
Entsprechend verhindert die shRNA-verursachte Verminderung der Snail-Produktion die 
HGF/SF-induzierte Zellmobilität. Die Erhöhung der Snail-Konzentration wird durch die 
Aktivierung der Mitogen-aktivierten Proteinkinase (MAPK) erreicht und durch den Trans-
kriptionsfaktor „early growth response factor“ (Egr)-1 vermittelt. Zusammenfassend 
konnte gezeigt werden, dass HGF/SF eine entscheidende Rolle in der Tumorzell-
disaggregation, -migration und schliesslich Invasion spielt. HGF/SF sollte daher als ein 
Kandidat für eine therapeutische Intervention betrachtet werden. 
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Summary 
 
Hepatocyte growth factor/scatter factor (HGF/SF) is a ubiquitously expressed 
molecule that elicits pleiotropic functions on epithelial cells, including mitogenic, 
motogenic, differentiating, angiogenic, and morphogenic effects. The receptor for 
HGF/SF is c-Met, a product of the proto-oncogene c-met, which is abundantly 
expressed in many tumors, rendering them highly receptive for HGF/SF signals. In 
hepatoblastoma (HB) and hepatocellular carcinoma (HCC), a high relapse incidence 
and post-operative residual tumor growth can be detected, when the serum levels of 
HGF/SF are markedly elevated, suggesting a link between this molecule and tumor 
malignancy. Although HB and HCC are two distinct subtypes of primary tumors arising 
from liver parenchymal cells and thus differ by many histo-clinical characteristics, 
comparative analysis of the impact of HGF/SF on these tumors may provide some clues 
on the oncogenic pathways leading to liver tumor progression. The results of this study 
demonstrate that HGF/SF mediates cytoprotective functions against the apoptotic 
inducers cisplatin, camptothecin, and starvation in a phosphoinositide 3-kinase (PI3K)-
dependent manner, thereby contributing to chemotherapy resistance. Differences 
between HB and HCC cells regarding the sensitivity towards HGF/SF and HGF/SF-
stimulated cellular responses were observed and are associated with c-Met expression. 
Furthermore, our experiments demonstrate that HGF/SF is a potent inducer of cell 
scattering and migration. HGF/SF triggers scattering of epithelial cells by upregulating 
the expression of Snail, a transcriptional repressor involved in epithelial-mesenchymal 
transition (EMT). Snail, which represses for example the expression of E-cadherin and 
claudin-3, is required for HGF/SF-induced cell scattering, since shRNA-mediated 
ablation of Snail expression prevents this process. HGF/SF-induced upregulation of 
Snail transcription involves activation of the mitogen-activated protein kinase (MAPK) 
pathway and requires the activity of early growth response factor (Egr)-1. Thus, HGF/SF 
plays a critical role in cell scattering, migration, and invasion. Together, these findings 
highlight the importance of HGF/SF in tumor cell survival and tumor progression and 
suggest that it should be considered as a candidate for therapeutic strategies. 
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1 Introduction 
1.1 Hepatoblastoma (HB) 
HB is the most frequent malignant primary hepatic tumor of early childhood, mainly 
affecting young children between six months and three years of age (Weinberg and 
Finegold, 1983). After neuroblastoma and nephroblastoma, primary epithelial tumors of 
the liver are the third most common intra-abdominal neoplasms in children (von 
Schweinitz et al., 2000; Clatworthy et al., 1974). HB has a fairly constant annual 
incidence of 0.5 – 1.5 diagnoses per 1 million children.  
Although the etiology of this tumor is still largely unknown, there is increasing 
evidence that it arises and differentiates from early hepatic progenitor cells, which in 
animals are known as oval cells. These cells still present morphologic features 
recapitulating some of the developmental aspects of the liver, yet escape from normal 
cell proliferation control. A disturbance of normal cell proliferation and differentiation 
during hepatogenesis is suspected, since HBs exhibit a wide spectrum of epithelial and 
mesenchymal lines of differentiation (differentiated-fetal, less differentiated-embryonal, 
small cell-undifferentiated). Neoplasms, which occur in these differentiation states, are 
believed to derive from a pluripotent stem cell (Marceau, 1990; Ruck et al., 1997). 
At diagnosis, a striking observation is that HB patients often show highly elevated 
serum levels of α-fetoprotein and hepatocyte growth factor/scatter factor (HGF/SF). In 
addition, an increase of up to fourfold HGF/SF was detected in 10 out of 12 children 24 -
 72 hours after liver resection (Lack et al., 1982; von Schweinitz et al., 1998; Weinberg 
and Finegold, 1983). This pre- and post-operative increase of HGF/SF serum levels is 
suspected to promote tumor cell proliferation and tumor progression after incomplete 
resection (von Schweinitz et al., 2000). Distant metastases occur mostly in the lungs 
(Perilongo et al., 2000), but metastasis of the central nervous system and even eye 
metastases have been described (Endo et al., 1996; Miyagi et al., 1984). Recently it 
was found, that a number of genetic conditions are related with an increased risk for 
developing HB, including Beckwith-Wiedemann syndrome, hemihypertrophy, and 
familial adenomatous polyposis (FAP) (Giardiello et al., 1996; Hartley et al., 1990).  
The incidence of HB is highly increased in FAP individuals (Hughes and Michels, 
1992; Polakis, 2000). FAP is an autosomal dominant disorder characterized by the 
development of colorectal adenomas during adolescence and young adulthood. If not 
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treated with prophylactic colectomy, colorectal cancer will develop in virtually all affected 
individuals before the fifth decade of life, accompanied with poor prognosis. The genetic 
disorder is caused by inherited germline mutations in the tumor suppressive adeno-
matous polyposis coli gene (APC) (Miyoshi et al., 1992). Loss of APC function promotes 
β−catenin translocation to the nucleus and activation of target genes, which are im-
portant in cell proliferation including c-myc, c-jun, and cyclin D1 (Bienz and Clevers, 
2000). It was previously reported that a significant subset (up to 48%) of sporadic HB 
harbors aberrations in various components of the Wnt/β-catenin pathway (see 1.7.7) 
(Koch et al., 1999; Polakis, 2000; Udatsu et al., 2001). This is one of the highest 
β-catenin mutation frequencies among solid tumors. Accordingly, nuclear accumulation 
of β-catenin and overexpression of its target genes is frequently found in HB (Koch et 
al., 2005).  
 Cytogenetic studies have shown that frequent loss of heterozygosity (LOH) at 
chromosomal locations 1p36 and 11p15.5 often occurs in HB. Loss of the maternal 
allele in the latter case indicates that this region is imprinted (Hartmann et al., 2000; 
Kraus et al., 1996). Two important genes are located on 11p15.5, namely insulin-like 
growth factor (IGF)-2 and H19, which are reciprocally imprinted. IGF-2 is expressed 
monoallelically from the paternal allele whereas H19 is expressed exclusively from the 
maternal allele (Giannoukakis et al., 1993; Zhang and Tycko, 1992). IGF-2 is a major 
fetal mitogen and growth factor whereas H19 codes for an untranslated RNA whose 
function is still under dispute (Barsyte-Lovejoy et al., 2006; Jones et al., 1998). Loss of 
imprinting (LOI) is an epigenetic alteration of the DNA, that leads to a biallelic 
expression predisposing cells to carcinogenesis and tumor growth. Accordingly, IGF-2 
mRNA expression was increased in HB, whereas the suppressor gene H19 mRNA is 
markedly reduced, suggesting a disruption of the reciprocal regulation of the imprinted 
genes in these tumors (Hartmann et al., 2000). 
 
1.2 Hepatocellular carcinoma (HCC) 
HCC is a malignant tumor, which arises from hepatocytes and accounts for a leading 
cause of worldwide cancer death with a 5-year survival rate of less than 5% without 
treatment (Parkin et al., 1999). Even when treated by resection, the recurrence rates are 
the highest of any solid tumor, approaching 75 – 100% (Tung-Ping Poon et al., 2000). 
HCC occurs mostly in people 50 to 60 years old and is more frequent in men than 
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Figure 1: Causes of hepatocellular 
carcinoma. Various risk factors can 
cause HCC (© 2006 The Johns Hopkins 
University, http://hopkins-gi.nts.jhu.edu/). 
women (2 - 4:1). It commonly develops in 
settings of liver cell injury, which leads to 
inflammation, hepatocyte regeneration, liver 
matrix remodeling, fibrosis, and ultimately, cir-
rhosis (Figure 1). Thereby, the vast majority of 
HCC worldwide (80%) is attributed to cirrhosis 
caused by alcohol abuse or other risk factors, 
including hepatitis B virus (HBV) and HCV in-
fection, hemochromatosis, fatty liver disease, 
androgenic steroid use, and other metabolic 
disorders (Akriviadis et al., 1998). Another high 
risk factor is the uptake of aflatoxin B1. This 
mycotoxin, produced by the fungus Aspergillus, contaminates food stored in humid 
conditions and is the most potent oncogenic agent for the liver (Sinha et al., 1988). 
The mechanisms by which these varied etiologies lead to cirrhosis and HCC are not 
well understood. Changed expression of growth factors and their receptors, along with 
overexpression of extracellular matrix (ECM) remodeling enzymes (matrix metallo-
proteinases, MMPs) are often seen in hepatic inflammation and chronic hepatitis. In 
general, this imbalance becomes more extensive as liver injury progresses through 
fibrosis, cirrhosis, or after surgical resection with subsequent cytokine and growth factor 
(e.g. HGF/SF) release and ischemia perfusion injury. 
To date, liver transplantation is the most promising curative treatment option for non-
virus-induced HCC, since systemic chemotherapy has low response rates and has 
never been shown to prolong patients’ survival. Overexpression of the multidrug 
resistance gene (mdr-1) makes HCC an inherently chemotherapy-resistant tumor 
(Llovet et al., 2003). Even repeated palliative treatment, such as chemoembolization 
cannot prevent the neoplasm progression, although it induces remarkable tumor 
necrosis. Finally, HCC has rarely been reported in patients younger than three years. In 
those patients the prognosis is much worse compared to the prognosis for patients with 
HB. 
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1.3 Hepatocyte growth factor/scatter factor (HGF/SF) 
 HGF/SF is a pleiotropic molecule that 
stimulates a wide variety of cellular re-
sponses including angiogenesis (Grant et 
al., 1993), cellular motility (Stoker et al., 
1987), growth (Stoker et al., 1987), in-
vasion (Jeffers et al., 1996), morpholo-
gical differentiation (Maina et al., 1997), 
embryological development (Schmidt et 
al., 1995; Uehara et al., 1995), tissue 
regeneration (Matsumoto and Nakamura, 
1993), and wound healing (Nusrat et al., 
1994). It is mainly expressed by mesen-
chymal cells (e.g. by surrounding fibro-
blasts) and acts primarily on epithelial 
cells (Figure 2).  
HGF/SF contains four kringle domains, each an 80-amino acid double-looped 
structure that is defined by three conserved disulphide bonds, and a serine proteinase 
homology domain, which lacks enzymatic activity. A similar structure is found in 
plasminogen, a circulating pro-enzyme which after activation is responsible for the lysis 
of blood clots. Like plasminogen, HGF/SF is secreted as a single-chain, biologically inert 
glycoprotein precursor and is proteolytically cleaved into an active heterodimer con-
sisting of a 60 kDa heavy chain and a 30 kDa light chain linked together by disulfide 
bonds (Figure 3) (Naldini et al., 1991). Conversion of pro-HGF/SF is mediated by 
several serine proteases including the plasminogen activators uPA (urokinase plasmi-
nogen activator) and 
tPA (tissue-type plas-
minogen activator), 
HGF activator, coagu-
lation factors X, XI, and 
XII, as well as a ho-
mologue of factor XII 
(Schwall et al., 1996).  
Figure 2: HGF/SF has multiple effects on 
cells. It controls a complex genetic program 
leading to cell-dissociation, migration in the 
extracellular matrix, growth, acquisition of 
polarity, tubule formation, survival, and 
apoptosis, depending on the concentration and 
cell type investigated. 
Figure 3: Structure of HGF/SF. HGF/SF is composed of α- and β- 
chains that are present after proteolytic cleavage. The α-chain 
contains four domains known as kringle (K1, K2, K3, K4), the signal 
peptide (SP) and the hairpin loop (HL). The β-chain contains the 
serine protease-like structure. Modified after (Trusolino and 
Comoglio, 2002) 
. 
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1.4 c-Met 
The c-Met receptor has originally been identi-
fied as the product of a human oncogene, tpr-met, 
resulting from chromosomal rearrangement. Here, 
the extracellular domain is replaced by a trans-
located promoter region (Tpr) sequence, which 
provides strong leucine-zipper dimerization mo-
tives leading to a constitutively active c-Met kinase 
activity (Cooper et al., 1984; Park et al., 1987). 
HGF/SF is the natural ligand for this receptor tyro-
sine kinase (RTK) c-Met, which is consistently ex-
pressed on most epithelial cells (Michalopoulos 
and Zarnegav, 1992). Since its initial charac-
terization as a proto-oncogene, c-Met has been 
shown as an important mediator of both normal 
and neoplastic invasive growth (Trusolino and 
Comoglio, 2002). In fact, inactivation of the 
HGF/SF or c-met genes in mouse causes 
embryonal lethality between E12.5 and E15.5 
(Maina et al., 2001; Schmidt et al., 1995). 
Like its ligand, the c-Met receptor is a 
disulphide-bridged heterodimer resulting from clea-
vage of a precursor molecule. The mature form of 
c-Met consists of an extracellular 50 kDa α-chain 
and a 185 kDa membrane-spanning β-chain. 
Recent mutagenesis experiments have shown that 
the α-chain and the first 212 amino acid residues of the β-chain are sufficient for HGF/SF 
binding (Gherardi et al., 2003). This region is homologous to the Sema-domain of the 
semaphorin axon-guidance proteins and might fold into a β-propeller structure. The 
intracellular domain also comprises the juxtamembrane (JM) and kinase domains as well 
as a carboxy-terminal domain that is essential for downstream signaling (Ponzetto et al., 
1994). The JM region contains a docking site, which can act as a negative regulator of 
c-Met function. c-Cbl, an E3 ubiquitin ligase, can bind to phosphorylated Y1003 within this 
region via its tyrosine kinase binding (TKB) domain followed by c-Met ubiquitination, 
Figure 4: The c-Met receptor tyrosine 
kinase. (A) The domain structure of c-
Met. S, sema domain; C, cysteine-rich 
domain; Ig, immunoglobulin domain; K, 
kinase domain; α and β refer to the 
subunits of the receptor that are 
present after proteolytic cleavage. (B) 
Three-dimensional models of the 
Sema, immunoglobulin and kinase 
domains of c-Met (Birchmeier et al., 
2003).  
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endocytosis, transport to the endosomal compartment, and finally degradation 
(Hammond et al., 2001; Jeffers et al., 1997; Peschard et al., 2001).  
Upon ligand binding c-Met is autophosphorylated on the two tyrosine residues Y1234/35, 
which enhance the intrinsic kinase activity, and phosphorylation of the tyrosine residues 
Y1349,1359 results in formation of a unique multi-substrate docking site that serves as 
signaling scaffold for various downstream effector molecules (see 1.6 for detailed 
description). Disturbance of the functional integrity of this activation process, e.g. by 
overactivation mutations, are a major cause for malignant tumors (Birchmeier et al., 
2003).  
The receptor activation is catalyzed by the kinase domain, which transfers the γ-phos-
phate group of ATP to tyrosine residues on protein substrates. Substrates of c-Met are 
multidomain proteins characterized by the presence of specific domains including the Src 
homology 2 (SH2), the phosphotyrosine binding (PTB) and Src homology 3 (SH3) 
domain. Some of the substrates that directly interact with c-Met include the growth factor 
receptor-binding protein (Grb) 2 (Ponzetto et al., 1994), STAT3 (Boccaccio et al., 1998), 
the p85 subunit of the phosphatidylinositol 3-kinase (PI3K) (Graziani et al., 1991), Shc 
(Pelicci et al., 1995), phospholipase C-γ (PLC-γ) (Weidner et al., 1990), c-Src (Ponzetto 
et al., 1994), and Grb2-associated binder (Gab)-1 (Weidner et al., 1990). All these 
molecules play an important role in the signal transduction and regulation of cellular 
functions as described below. 
 
1.5 c-Met signal transduction 
Stimulation of the c-Met receptor has been linked to cellular responses associated 
with invasive behavior, such as cell dissociation, migration, scattering and reduced 
cellular adhesion, but also stimulation of cell proliferation and survival. Epithelial cells, in 
particular the Madin-Darby canine kidney (MDCK) cell line, respond to HGF/SF with 
scattering, i.e. colony dispersal, increased motility, and invasion into collagen or matrigel 
matrices (see (Thiery, 2002) for review). Moreover, MDCK cells, when cultured within a 
collagen matrix, form tubular structures upon HGF/SF stimulation (Boccaccio et al., 
1998). Tubular branching is a complex morphogenic coordination of cell growth, polarity, 
and movement and not yet completely understood.  
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Many attempts have been undertaken to 
define the role of each individual down-
stream effector pathway in specific cellular 
responses to c-Met activation. Early experi-
ments showed that specific inhibitors of the 
ERK/MAPK or PI3K pathways could inhibit 
scattering of epithelial cells, indicating that 
both are important in disassembly of the 
adherens junctions, cell spreading and 
motility (Potempa and Ridley, 1998). 
An unique facet of c-Met relative to other 
RTKs is its reported interaction with focal 
adhesion complexes and non-kinase binding 
partners such as β4-integrins, CD44, and 
semaphorins, which may further add to the 
complexity of regulation of cell function by 
this receptor (Giordano et al., 2002; 
Trusolino et al., 2001; van der Voort et al., 
1999). However, these binding partners do not seem to be essential for short-term 
HGF/SF signaling, but might contribute to sustained c-Met activation (DiGabriele et al., 
1998; Hartmann et al., 1998; Schwall et al., 1996). 
 
1.6 Adaptor proteins 
Upon phosphorylation of the unique Y1349,1359 docking site, several substrates can bind 
to the c-Met receptor. Most contain the Src-homology domain SH2, which predominately 
mediates these interactions. For steric reasons two substrates cannot simultaneously 
bind to the bidenate site of one c-Met molecule (Stefan et al., 2001).  
1.6.1 Grb2 
Growth factor receptor binding protein (Grb) 2 is a small adaptor protein comprised 
of an SH2 domain flanked by two SH3 domains and thus is also able to bind to proline-
rich ligands (Goudreau et al., 1994; Terasawa et al., 1994). Grb2 binding to the 
guanine nucleotide exchange factor (GEF) son-of-sevenless (SOS) establishes a link 
Figure 5: Signaling pathways of Met. 
c-Met's activity is controlled by various down-
stream signaling molecules. Phosphatidylino-
sitol 3-kinase (PI3K)-dependent signaling 
results in cell mobility and survival. Activation of 
the Grb2-SOS-Ras cascade leads to cell pro-
liferation, whereas Jak/STAT (Janus kinase, 
Signal Transducers and Activators of Trans-
cription), PLC-γ (phospholipase Cγ), and SHP2 
(protein tyrosine phosphatase) are substantial 
for transformation processes (Trusolino and 
Comoglio, 2002). 
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between the RTK and Ras signaling with subsequent activation of the Raf-MEK1/2-
ERK1/2 pathway (Li et al., 1993; Maina et al., 2001). 
The c-Met receptor can only recruit one Grb2 through the SH2-domain-binding site 
at the tyrosine residue Y1356 (Fixman et al., 1997). When the adaptor protein Shc is 
recruited and phosphorylated by the c-Met receptor, it can bind two Grb2 molecules 
through its SH2 domains (Rozakis-Adcock et al., 1993). This leads to an amplification of 
Grb2 downstream pathways and can also strengthen the binding of Gab1 (see below) to 
the c-Met-Shc-(Grb2)2  complex. Notably, Grb2 binding to c-Met is not essential for c-
Met signaling in embryogenesis, indicating only a minor or enhancing role in the 
transmission of c-Met signals at this stage of development (Ieraci et al., 2002). 
1.6.2 Gab1 
Grb2-associated binder (Gab)-1 is a versatile scaffolding adaptor protein, which 
binds to the phosphorylated tyrosine residue Y1349 of the c-Met receptor, but can also be 
indirectly recruited through Grb2. Gab1 is the most crucial substrate for c-Met signaling, 
since it binds signal-relay molecules, such as SH2-domain-containing protein tyrosine 
phosphatase2 (Shp2), PI3K, phospholipase C and Crk (Gu and Neel, 2003; Maroun et 
al., 1999; Sachs et al., 2000). Both Crk and Crk-like kinases bind to specific motifs in 
Gab1 and recruit C3G, a guanine-nucleotide exchange factor that regulates adherent 
junction positioning and cell adhesion by activating Rap1 (Knox and Brown, 2002; 
Knudsen et al., 1994). 
Knock-out studies of Gab1 revealed the same phenotypes as observed in c-met -/- 
mice, indicating an essential role of Gab1 in c-Met-mediated signaling (Sachs et al., 
2000). Indeed, recent experiments demonstrate that Gab1 is necessary for the c-Met-
mediated induction of cell-cycle progression, proliferation, and oncogenic morphological 
transformation (Mood et al., 2006). Notably, Gab1 also participates in the transmission 
of signals from other receptors, which is reflected by the presence of additional 
phenotypes in Gab1-mutant mice that are absent in c-met-mutant mice (Itoh et al., 
2000). However, a prolonged Gab1 phosphorylation, as it was observed in c-Met 
coupling, cannot be evoked by other growth factors (e.g. epidermal growth factor, EGF) 
(Maroun et al., 1999). 
1.6.3 Shc 
Another important mediator of cell transformation downstream of c-Met is the 
adaptor protein Shc, which associates with c-Met and other RTKs as well. Upon 
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recruitment, Y239/240 and Y317-phosphorylated Shc binds to the SH2 domain of Grb2 to 
facilitate downstream responses, including activation of Ras-Raf-ERK-1/2 and PI3K/Akt 
pathways. In addition, although Grb2 can directly bind to RTKs, activation of some inde-
pendent downstream signaling pathways relies on Shc’s indirect recruitment of Grb2. 
Hence, Shc can activate and regulate distinct biological functions, e.g. c-Met-stimulated 
vascular endothelial growth factor (VEGF) production depends on the recruitment of Shc 
and not Grb2 (Saucier et al., 2004).  
Shc was initially identified as an SH2 containing proto-oncogene involved in growth 
factor signaling and thus hyper-phosphorylation of Shc has been seen in many different 
types of tumors, suggesting a crucial role in signal transduction (Ravichandran, 2001). 
 
1.7 Activated downstream signaling cascades 
1.7.1 Shp2 
The SH2 domain containing tyrosine phosphatase (Shp2) is an important mediator 
of the ERK/MAPK pathway (Gu and Neel, 2003; Schaeper et al., 2000). It normally has 
a low basal tyrosine phosphatase activity due to allosteric inhibition of its amino-terminal 
SH2 domain. Only when phosphorylated tyrosine residues of Gab1 bind to the SH2 
domains of Shp2, is the inhibition relieved (Cunnick et al., 2002). Experimental data 
show that a membrane-targeted (but not a cytoplasmic) mutant of Shp2 is sufficient to 
activate Ras and the ERK/MAPK pathway, whereas a mutant form of Gab1 that lacks 
the Shp2 binding sites blocks sustained but not transient activation of ERK/MAPK 
(Cunnick et al., 2002; Maroun et al., 2000). Shp2 possibly also has an adaptor function, 
given that Grb2 associates with phosphorylated tyrosine residues upon ligand 
stimulation (Vogel and Ullrich, 1996). 
 
1.7.2 Ras-Raf-ERK/MAPK pathway 
The mitogen-activated protein kinases (MAPKs) are important signal transducing 
enzymes connecting cell surface receptors to critical regulatory targets within the cell. 
They phosphorylate specific serine and threonine residues of target proteins thereby 
controlling cell proliferation, differentiation and transformation (Chang and Karin, 2001; 
Garrington and Johnson, 1999; Johnson and Lapadat, 2002). MAPKs also respond to 
chemical and physical stress, thus mediating cell survival and adaptation. At least four 
Introduction 
16 
distinctly regulated groups of MAPK are expressed in mammals, extracellular-regulated 
kinase-1/2 (ERK-1/2), Jun amino-terminal kinase (JNK 1/2/3), p38 proteins (p38α,β,γ,δ) 
and ERK5 (Chang and Karin, 2001). 
In c-Met-induced signal transduction, MAPKs are activated through the 
Gab1/Grb2/SOS/Ras pathway: c-Met phosphorylation leads to the recruitment of Gab1 
and Grb2 and association and activation of the Ras-GEF SOS, which in turn activates 
membrane-associated Ras. Ras then induces serine/threonine kinase activity of the 
MAPK kinase kinase (MAPKKK) Raf-1, which phosphorylates and activates MAPK 
kinases 1/2 (MEK-1/2). MEK-1/2 finally activate ERK-1/2 by phosphorylation of thre-
onine and tyrosine residues in the regulatory Thr-Glu-Tyr (TEY) motif (Robinson and 
Cobb, 1997). ERK-1/2 then translocate to the nucleus to phosphorylate and activate 
transcription factors. 
The ERK/MAPK pathway is a critical mediator of HGF/c-Met signaling and required 
for HGF/SF-elicited cell scattering, adherens junctions disassembly, proliferation and 
tubulogenesis (Khwaja et al., 1998; Potempa and Ridley, 1998; Schaeper et al., 2000; 
Tanimura et al., 1998). 
 
1.7.3 PI3K-Akt/PKB 
Phosphatidylinositol-3 kinases (PI3Ks) have a central function in the control of 
metabolism, cell growth, proliferation and survival. The so-called class IA isoforms of 
PI3Ks are tightly associated with the p85 regulatory subunit that contains two SH2 
domains with a high affinity for phosphorylated tyrosine residues of c-Met and other 
RTKs, as well as adaptor proteins (e.g. Gab1). Once activated, the 110 kDa-subunit of 
PI3K is brought in close proximity of the plasma membrane. There, it catalyzes the 
phosphorylation of membrane-bound phosphatidylinositol-4,5-bisphosphate (PIP2) at the 
3' position of the inositol ring, producing the second messenger phosphatidylinositol-
3,4,5-trisphosphate (PIP3). The generation of PIP3 subsequently causes translocation of 
PIP3-binding proteins to the plasma membrane (reviewed in Wymann et al., 2003). 
Many of these molecules bind to PIP3 through a pleckstrin homology (PH) domain, 
including the proto-oncogenic protein kinase B (PKB), also known as Akt (Brazil and 
Hemmings, 2001). The activation of class I PI3Ks is counteracted by phosphoinoside 
phosphatases, such as PTEN, which dephosphorylate PIP3 to PIP2 (Brazil and 
Hemmings, 2001; Wymann et al., 2003). 
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Akt/PKB, besides its effects on glucose transport and activation of glycogen 
synthesis and glycolysis, promotes growth factor-mediated cell survival and anchorage-
independent growth, both directly and indirectly. Akt/PKB-mediated phosphorylation of 
Bad, the pro-apoptotic Bcl-2 family member, leads to Bad dissociation from the 
Bcl-2/Bcl-xL complex, thereby loosing its pro-apoptotic function (Dudek et al., 1997; Fan 
et al., 2000; Franke et al., 1997b; Frisch and Francis, 1994; Igney and Krammer, 2002; 
Porter and Vaillancourt, 1998; Xiao et al., 2001). 
HGF/SF-induced PI3K/Akt signaling is required for scattering and branching morpho-
genesis in many cell types (Ponzetto et al., 1994; Royal and Park, 1995). Over-
expression of a constitutively active form of PI3K is sufficient to induce in vitro scattering 
and branching morphogenesis of MDCK cells (Khwaja et al., 1998). 
Another target of Akt/PKB is the glycogen synthase kinase-3β (GSK-3β). Phospho-
rylation of GSK-3β leads to its inactivation, thus preventing the association of GSK-3β, 
APC and free β-catenin and the successive degradation of β-catenin (see 1.7.7) (Bienz 
and Clevers, 2000; Polakis, 2000). 
 
1.7.4 Jak/STAT pathway  
The Janus kinase (Jak) family of cytokine receptor-associated protein tyrosine 
kinases and the signal transducer and activator of transcription (STAT) proteins have 
diverse biological functions, including roles in cell differentiation, proliferation, develop-
ment, apoptosis, and inflammation (Figure 6)(Ishihara and Hirano, 2002). Thus, STAT 
proteins are induced by a wide variety of growth factors and cytokines (Levy et al., 
1988). Ligand binding to the cognate receptor results in activation of members of the 
Jak family (Shuai et al., 1993) and tyrosine phosphorylation of STAT proteins. The latter 
then form homo- or heterodimers through their SH2-domains, and translocate to the 
nucleus, where they preferentially bind to response elements in the promoters of target 
genes and activate transcription (Sadowski et al., 1993; Shuai et al., 1993). 
Aberrations in STAT signaling are found in numerous cancers and therefore this 
pathway is a potential target for anticancer therapy (Haura et al., 2005). Constitutive 
activation and increased levels of STAT3 has been linked to increased survival of tumor 
cells and thus have been found in many human malignancies (Turkson and Jove, 2000). 
Constitutive activation of both STAT1 and STAT5 accompanies transformation of many 
cell types (Bowman et al., 2000). 
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The role of the Jak/STAT pathway in 
c-Met signaling is controversial. Direct 
binding of STAT3 to the c-Met receptor 
and a requirement for STAT3 in the 
c-Met-dependent formation of branched 
tubules have been reported (Boccaccio 
et al., 1998). However, other studies 
support STAT3 activation independent 
of c-Met binding, e.g. in anchorage-
independent growth (Schaper et al., 
1997; Zhang et al., 2002). 
 
1.7.5 Src 
The non-receptor tyrosine kinase 
c-Src is required for the loss of intra-
cellular junctions and gain of cell-matrix 
adhesion during HGF/SF-dependent 
scattering and migration responses 
(Ponzetto et al., 1994). Following 
HGF/SF stimulation, c-Src associates 
with c-Met and mediates cell motility and 
anchorage-independent growth by phos-
phorylating the tyrosine residues in the 
short cytoplasmic domain of E-cadherin, 
leading to its internalization (Pece and 
Gutkind, 2002). Other substrates of 
c-Src include focal adhesion kinase 
(FAK) and the adapter protein p130Crk-
associated substrate (p130Cas), both 
involved in cell adhesion, migration and 
transformation (Cary et al., 1998). 
Analogously, in non-metastatic murine 
mammary carcinoma SP1 cells, where 
Figure 6: Three examples of signaling in the 
JAK-STAT pathway. 
Specific ligand-receptor interactions generate 
active transcription complexes composed of 
distinct STAT proteins. Left: Type II IFN (IFN-γ) 
binding induces receptor tyrosine phospho-
rylation (P) by JAK1/2 proteins, producing a 
recruitment site for STAT1. STAT1 dimers 
translocate to the nucleus and activate trans-
cription from IFN-γ target gene promoters 
containing IFN-γ activation sites (GAS). Center: 
Type I IFNs (IFN-α or IFN-β) stimulate the 
activity of JAK1 and TYK2 proteins, leading to 
STAT2 tyrosine phosphorylation. The STAT2 
phosphotyrosine is a docking site for latent 
STAT1. The activated factor ISGF3 is a hetero-
trimer of STAT1 and STAT2 in association with 
IFN regulatory factor (IRF)-9, which alone can 
enter the nucleus, but is retained in the 
cytoplasm by interactions with STAT2. Right: 
IL-6 activates JAK1 and JAK2, producing a 
phosphotyrosine docking site for STAT3. 
STAT3 dimers translocate to the nucleus and 
activate transcription from target gene 
promoters containing a GAS-like element, 
sometimes referred to as the serum-inducible 
element (SIE). IL-6 also activates STAT1, 
leading to homo- and heterodimers of STAT1 
and STAT3 (not illustrated; Aaronson and 
Horvath, 2002). ISRE, interferon-stimulated 
response element. 
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c-Src kinase activity is significantly reduced, HGF/SF-induced motility is blocked (Rahimi 
et al., 1998). 
 
1.7.6 Phospholipase C-γ (PLCγ) 
PLCγ is another adaptor protein that directly binds to the phosphorylated tyrosine 
residue Y1356 of the c-Met receptor, but can also bind to Grb2. Although it is not essential 
for HGF/SF-induced scattering or proliferation of MDCK cells (Royal et al., 1997), it was 
concluded that sustained recruitment of PLCγ to Gab1 plays an important role in 
branching tubulogenesis (Gual et al., 2000). Furthermore, PLCγ has been shown to be 
involved in growth factor-induced mitogenesis, differentiation, development, metabolism, 
secretion, contraction and sensory perception (Noh et al., 1995; Thackeray et al., 1998; 
Wang et al., 1998). 
PLCγ forms stable complexes with RTKs through its SH2 domains (Anderson et al., 
1990; Margolis et al., 1990). After activation by tyrosine phosphorylation, PLCγ 
hydrolyzes PIP2 to form inositol-1,4,5-triphosphate (InsP3) and diacylglycerol (DAG). 
InsP3 stimulates the release of calcium ions from internal stores (Berridge et al., 1998; 
Lipp and Niggli, 1996) and DAG activates protein kinase C (PKC) (Wahl and Carpenter, 
1991). The correct balance of calcium between the endoplasmic reticulum and the 
mitochondria is necessary for cell survival (Berridge et al., 1998; Dolmetsch et al., 
1998). Loss of this equilibrium, e.g. by a decrease in InsP3 production, could be lethal 
for cells. 
 
1.7.7 Wnt/β-catenin pathway 
The highly conserved canonical Wnt/β-catenin pathway plays important roles in 
development and is frequently found upregulated in tumors (Bienz and Clevers, 2000; 
Polakis, 2000). In the absence of Wnt signals, β-catenin, in a complex with APC and 
Axin, is phosphorylated on serine/threonine residues by the GSK-3β and targeted for 
ubiquitin/proteasome-mediated degradation by the β-transducin-repeat-containing 
protein (β-TrCP). Upon Wnt binding to Frizzled receptors, Disheveled is activated, which 
subsequently blocks β-catenin degradation (Figure 7). Excess β-catenin translocates to 
the nucleus where it interacts with the HMG-box transcription factor TCF to modulate 
transcription of several target genes, such as cyclin D1, c-myc, c-jun, TCF-1, MMP-7, 
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CD44, β-TrCP, and Slug 
(Bienz and Clevers, 2000; 
Conacci-Sorrell et al., 2003; 
Nelson and Nusse, 2004; 
Polakis, 2000). 
The other central role of β-
catenin is its function in the 
adhesion complex. As a 
member of adherens junc-
tions it is, like γ-catenin, 
sequestered by cadherins 
and linked to the cytoske-
leton, thereby mediating tight 
intercellular adhesion. Three 
conserved tyrosine residues 
in β-catenin regulate the inte-
grity of the cadherin core 
complex: Y142, Y489, and Y654 
(Aberle et al., 1996). 
Phosphorylation of these resi-
dues results in dissociation of 
α-catenin from β-catenin with 
concomitant loss of cadherin 
adhesion. Liberated tyrosine-phosphorylated β-catenin does not interact with Axin 
(Danilkovitch-Miagkova et al., 2001), thereby possibly inhibiting its ubiquitination and 
degradation through the proteasomal pathway, which finally leads to an accumulation of 
unbound phospho-β-catenin.  
When E-cadherin function is lost, β-catenin is liberated from the adhesion core 
complex and serine-phosphorylated in the APC/Axin/GSK-3β-complex, resulting in its 
proteasomal degradation (Danilkovitch-Miagkova et al., 2001). 
Notably, there is a pool of β-catenin that is especially targeted by the HGF/SF 
receptor c-Met (Brembeck et al., 2004). Binding of HGF/SF induces phosphorylation of 
β-catenin at the tyrosine residue Y142, releasing the protein from a membrane-associated 
pool to associate with Bcl9-2, a Drosophila Legless homologue, which is responsible for 
Figure 7: The link between E-cadherin-mediated cell–cell 
adhesion and the WNT signalling pathway.  
In the absence of Wnt stimulation, the adenomatous polyposis 
coli (APC)/Axin/glycogen synthase kinase 3β (GSK-3β)/ 
complex earmarks β-catenin (β, red) for degradation by the 
proteasome. The levels of cytoplasmic β-catenin are low, and 
T cell factor (TCF) is repressed. After Wnt stimulation of the 
Frizzled (FRZ) receptor, Dishevelled (Dsh) is recruited to the 
membrane where it binds to Axin to inhibit the APC/Axin/GSK-
3β complex. β-catenin accumulates and, after translocation 
into the nucleus, binds to TCF transcription factor to co-
activate Wnt target genes. β-catenin is also involved in the 
formation of adherens junctions. These junctions are formed 
by the transmembrane protein E-cadherin, which is linked to 
the actin cytoskeleton by β-catenin and α-catenin (α, orange). 
EGF, epidermal growth factor; HGF, hepatocyte growth factor; 
P, phosphate; p120, p120CAS; SRC, SRC tyrosine kinase 
(Christofori and Semb, 1999). 
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escorting β-catenin into the nucleus. This occurs concomitantly with the conversion of 
MDCK cells expressing Bcl9-2 to a mesenchymal phenotype (Brembeck et al., 2004). 
These data are consistent with prior findings, where oncogenic c-Met mutations resulted 
in the accumulation of β-catenin and increased transcription of β-catenin/TCF target 
genes. Accordingly, in many cancer cells, loss of function of the tumor suppressor APC, 
mutations in β-catenin or inhibition of GSK-3β has been found associated with over-
expression of proto-oncogenes. 
Also for HB and HCC, frequent mutations of β-catenin and Axin resulting in the 
prevention of degradation and nuclear accumulation of β-catenin and activation of 
oncogenic target genes have been reported (Clevers, 2000; Koch et al., 1999; Polakis, 
2000; Satoh et al., 2000).  
The HGF/c-Met-mediated increase of oncogenic β-catenin/TCF target gene 
expression may play a pivotal role during EMT and tumorigenesis (Danilkovitch-
Miagkova et al., 2001; Muller et al., 2002). However, to date it is not clear whether the 
translocated β-catenin originates from released E-cadherin/β-catenin junctions or 
whether c-Met is surrounded by its own pool of β-catenin as suggested by Monga and 
colleagues (Monga et al., 2002).  
 
1.8 Transcription factors 
A frequent downstream event of signaling cascades is the activation of transcription 
factors, which bind to promoters of genes and thus mediate transcription of target 
genes. In HGF/c-Met-triggered cellular responses several transcription factors are 
involved, including c-Fos, Egr-1, JunB, JunD, and c-Myc (Johnson et al., 1995; Maffe 
and Comoglio, 1998; Recio and Merlino, 2003; Weir et al., 1994). Dysregulation of 
signaling cascades often leads to overactivation of transcription, which is considered as 
another hallmark of cancer (Hanahan and Weinberg, 2000). 
1.8.1 AP-1 
Transcription factors like c-Fos and c-Jun, which belong to the activated protein-1 
(AP-1) transcription factor family, are responsible for a variety of cellular responses 
upon growth factor stimulation. It was previously shown that HGF/SF-induced AP-1 
binding results from post-translational modification of c-Jun protein or expression of 
other members of the AP-1 family or both. In particular the activation of the Ras/MAPK 
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pathway by HGF/SF results in activation and stimulation of mRNA expression of AP-1 
family members (e.g. c-jun and c-fos) (Maffe and Comoglio, 1998; Weir et al., 1994). 
Moreover, by electrophoretic mobility shift assays (EMSA), an AP-1 binding site 
(TGAGTCA) was identified as the responsive element within the c-met core promoter 
region at position -158 to -152 (Seol et al., 2000), indicating that c-Met induces a 
positive feedback loop. 
 
1.8.2 Egr-1 
The early growth response factor (Egr)-1 [also known as NGFI-A, Krox-24, and 
Zif268] encodes a nuclear, 82 kDa zinc finger protein capable of binding to specific GC-
rich DNA sequences containing the consensus binding code GCG(G/T)GGGC, and it is 
known to regulate various genes, especially those important in injury stimuli (Sukhatme 
et al., 1988; Sukhatme et al., 1987). Egr-1 recognition elements were predominantly 
identified in promoters of genes encoding growth factors, cytokines and their receptors, 
and cell cycle control genes (for review see (Silverman and Collins, 1999)). Recently it 
was demonstrated that HGF/SF upregulates pro-angiogenic factors, such as PDGF and 
VEGF (Worden et al., 2005), CD44v6 (Recio and Merlino, 2003), and angiotensin 
converting enzyme (ACE) (Day et al., 2004), as well as fibronectin (Gaggioli et al., 2005) 
through Egr-1 in a MAPK-dependent manner. Other target genes of Egr-1 play a vital 
role in cellular growth, development, and differentiation and include HGF/SF, TGFβ-1, 
FGF, IGF-II, TNF-α, IL-1β, and plasminogen activator inhibitor (PAI)-1 (Houston et al., 
2001). 
NGFIA-binding proteins (Nab)-1 and -2 tightly regulate the expression and function 
of Egr-1. While Nab-1 is constitutively expressed, Nab-2 is activated by the same 
signals as Egr-1 and by Egr-1 itself (Kumbrink et al., 2005). Nab-2 not only inhibits 
Egr-1 binding to DNA, it also directly interacts with the Egr-1 promoter (Cao et al., 
1993), thereby providing a strong negative feedback loop. 
 
In summary, HGF/SF is capable of activating several pathways and inducing 
transcription of various target genes. The final biological outcome, however, depends on 
which pathway is activated and which co-signals derive from the cell microenvironment. 
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1.9 Mechanisms of apoptosis 
In multicellular organisms, apoptosis is a naturally occurring process that is crucially 
involved in organogenesis and removal of altered or infected cells. Thus, it prevents the 
pathogenesis of various diseases such as cancer.  
In this process, aspartate-specific proteases, the so-called caspases are the main 
effectors (Thornberry and Lazebnik, 1998). One mechanism to trigger these caspases is 
by ligand binding to the tumor necrosis factor (TNF) receptor family. This stimulation 
results in activation of the initiator caspase 8, which in turn activates the effector 
caspase 3.  
Other apoptotic triggers, such as UV-radiation, γ-radiation, disruption of cell 
attachment, a process termed anoikis, or exposure to chemicals, lead to drastic 
changes of the mitochondria. Mediators include proteins of the Bcl-2 family, which 
consists of pro- and anti-apoptotic members. Among them are the pro-apoptotic proteins 
Bax and Bid as well as the anti-apoptotic protein Bcl-xL, and Bcl-2 itself. When Bax is 
activated, its conformational change leads to an oligomerization at the outer membrane 
of the mitochondria and to pore formation. This promotes the efflux of cytochrome c and 
a second mitochondria-derived activator of caspases (Smac) into the cytoplasm. 
Cytochrom c, together with the apoptotic peptidase activating factor (APAF)-1 and 
caspase 9 form the so-called apoptosome. Subsequently, caspase 9 is activated, which 
then in turn activates caspase 3. Activated caspase 3 finally leads to destruction of 
cellular structures and causes cell death. Since activation of caspase 3 is a late event in 
apoptosis and is activated by both signaling pathways, it is a unique protein to study 
apoptosis (Frisch and Francis, 1994; Hengartner, 2000; Igney and Krammer, 2002). 
 
1.10 EMT/ scattering/ invasion 
Invasion of surrounding tissues and metastasis to distant organs have long been 
recognized as hallmark features of malignant cancers (Hanahan and Weinberg, 2000). 
Metastasis is a multi-step process characterized by dissociation of tumor cells from the 
epithelial layer, penetration through the basement membrane into the adjacent 
connective tissue, intravasation, survival in the blood stream, extravasation at a distant 
site and colonization of new terrain, with stimulation of neo-angiogenesis (Chambers et 
al., 2002). In this process, the downregulation of adherens and tight junction proteins is 
a prerequisite. The central member of such adhesion junctions is the calcium-dependent 
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Figure 8: EMT in tumor progression.  
During the multi-step process of epithelial-mesenchymal 
transition (EMT) early stage tumor cells (green) become 
more motile by accidental overexpression of EMT 
regulators (purple nuclei) resulting in downregulation of 
adhesion proteins like cadherins and catenins and 
concomitantly upregulation of mesenchymal markers   
(Kang and Massague, 2004). 
homophilic transmembrane pro-
tein E-cadherin. Intracellularly it is 
directly bound to β-catenin 
through the cytoplasmic domain. 
α-catenin then links the N-ter-
minal region of β-catenin to 
α-actinin, and to several actin-
binding proteins, e.g. zonula 
occludens (ZO)-1 and vinculin, 
suggesting that it plays a crucial 
role in organizing actin filaments 
at adherens junctions. However, it 
seems that the exact role of 
α-catenin has been misjudged so far (Burridge, 2006).  
Loss of cell-cell-adhesion together with morphological changes, loss of apico-
basolateral cell polarization, induction of cell motility, decrease in cell-matrix-adhesion, 
and changes in the production or distribution of specific proteins, e.g. desmoplakin and 
vimentin, are typical characteristics of the epithelial-mesenchymal transition (EMT) 
(Grunert et al., 2003; Thiery, 2002). 
 
  Table 1: Phenotypic modules of EMT and metastasis 
category transitioning event phenotypic module 
Epithelial release Disintegration of cell-cell contacts 
Loss of cell polarity 
Repression of epithelial markers 
Migration Cytoskeletal reorganization 
Locomotion 
Chemoattraction 
EMT 
Invasiveness Basement membrane degradation 
Interstitial matrix degradation 
Interstitial matrix synthesis 
Intravasation/ extravasation Anoikis resistance 
Apoptosis resistance 
Endothelial cell adhesiveness 
Metastasis 
Metastatic growth Autonomus growth potential 
Angiogenesis factors 
(adapted from: Zavadil and Bottinger, 2005) 
 
Introduction 
25 
EMT plays a pivotal role during development by which epithelial cells acquire 
mesenchymal, fibroblast-like properties and show reduced intercellular adhesion and 
increased motility. Accumulating evidence points to a critical role of EMT-like events 
during tumor progression and malignant transformation, endowing the incipient cancer 
cell with invasive and metastatic properties (Boyer et al., 2000). During development, 
tissue repair, and tumor metastasis, both cell-cell dissociation and cell migration occur 
and appear to be intimately linked (see  Table 1). 
In cancer progression, oncogenic EMT refers to clusters of malignant cells with 
altered epithelial characteristics and acquired, self-sustained migratory and highly matrix 
invasive phenotype. Oncogenic EMT is well documented in vivo and typically believed 
as complete and irreversible, in contrast to the reversible EMT observed during 
embryogenesis (Zavadil and Bottinger, 2005). 
Loss of E-cadherin function is 
a key element in EMT, and thus 
E-cadherin is considered a tumor 
suppressor for two reasons: tran-
scription of its gene is silenced in 
various carcinomas, and repres-
sion of a native form of E-cad-
herin in carcinomas is sufficient to 
reduce the aggressiveness of 
tumor cells (Cavallaro and 
Christofori, 2004; Perl et al., 
1998). Furthermore, there is a 
good correlation between the 
process of invasion and metas-
tasis and loss of E-cadherin at 
the cell surface of cancerous 
cells (Birchmeier and Behrens, 
1994). 
Cadherins generally are regu-
lated at both the mRNA and protein levels, by means of changes in subcellular 
distribution, translational or transcriptional events, and degradation. Normally, E-cad-
herin is repressed by transcriptional repressors that bind to the consensus sequence 
Figure 9: Regulation of Snail.  
The function of Snail is tightly regulated by its stability, 
subcellular localization and different phosphorylation 
events. The subcellular localization is governed by the 
GSK-3β. GSK-3β phosphorylates serine residues, which 
is a signal for nuclear export and for ubiquitination and 
degradation, respectively.  
ILK, integrin-linked kinase; PAK1, p21-activated kinase; 
GSK-3β, glycogen synthase kinase; TGF, transforming 
growth factor; EGF, epidermal growth factor; MTA3, 
metastasis-associated protein 3, ROS, reactive oxygen 
species; ER, estrogen receptor; LOXL, lysyl oxidase-like 
enzyme; CK8, cytokeratin 8. 
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CANNTG (termed E-box) in the E-cadherin promoter. Transcriptional repressors include 
the zinc-finger transcription factors Snail and Slug (Bolos et al., 2003; Cano et al., 2000; 
Nieto, 2002), δEF-1/ZEB-1 (Eger et al., 2005), and SIP-1/ZEB-2 (Comijn et al., 2001; 
Peinado et al., 2004). In addition, the highly conserved basic helix-loop-helix (bHLH) 
transcription factors Twist (Yang et al., 2004) and E12/47 (Cano et al., 2000; Perez-
Moreno et al., 2001) were also found to control E-cadherin expression. Sugimachi et al. 
found an inverse correlation between the expression of Snail and E-cadherin in HCCs. 
Moreover, Snail overexpression and E-cadherin downregulation were associated with 
higher cancer invasiveness, suggesting a central role for Snail in tumor progression and 
metastasis (Figure 9) (Sugimachi et al., 2003). 
Besides mediating adhesion junctions, Snail has also been linked to loss of tight 
junction proteins such as claudins, occludin, and ZO-1 (Ikenouchi et al., 2003; Ohkubo 
and Ozawa, 2004). In addition, Snail positively controls genes significantly involved in 
tissue remodeling, e.g. fibronectin, vimentin, RhoGTPases, and MMPs (Nieto, 2002). 
 
1.11 c-Met, HGF/SF, and cancerogenesis 
HGF/SF-triggered cell scattering and migration recapitulates many of the events that 
occur during cancer invasion, as tightly clustered epithelial cells break their cell-cell 
junctions and become single, migrating, invasive cells. Thus, dysregulation of c-Met and 
HGF/SF by mutation, gene rearrangement, gene amplification, constitutive kinase 
activation, and overexpression have been implicated as causative factors in the 
development and progression of numerous human cancers, including lung, breast, 
colorectal, prostate, pancreatic, gastric, hepatocellular, ovarian, renal, glioma, 
melanoma, and some sarcomas (see Table 2 for a comprehensive list). Activation of 
c-Met in cancer occurs most often through ligand-dependent autocrine or paracrine 
mechanisms and unfortunately, this over-activation often correlates with poor prognosis 
(Birchmeier et al., 2003). 
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Furthermore, ligand-independent activation of c-Met is also possible, e.g. by activating 
mutations (Park et al., 1987). c-Met overexpression also has been attributed to a 
number of epigenetic mechanisms including tumor-secreted growth factors, tumor 
hypoxia, and activation of other oncogenes, e.g. activated Ras (Furge et al., 2001; Ivan 
et al., 1997). Further proof of the involvement of HGF/c-Met signaling in tumor 
progression comes from several in vitro and in vivo studies. Mouse and human cell lines 
that ectopically overexpress HGF/SF or c-Met, or both become tumorigenic and 
metastatic in athymic nude mice (Rong et al., 1994). 
Table 2: HGF/SF, c-Met and cancer references 
The table shows significant references related to the roles of HGF/SF or c-Met in the types of 
cancer indicated. For each cancer type, headings correspond to studies showing: HGF/SF 
expression in tumor biopsies, c-Met expression in tumor biopsies, expression of HGF/SF or c-Met 
correlating with poor prognosis, sporadic or germline-activating mutations in c-Met, tumor cells in 
vitro expressing c-Met or HGF/SF, some with correlations to in vitro neoplastic-like activities, and 
animal models supporting the role of c-Met and HGF/SF in cancer, including human tumor xeno-
grafts in immunocompromised mice, mice with HGF/SF or c-Met transgenes, or other animal 
models displaying dependence on HGF/SF or c-Met in cancer development. A, autocrine; MFH, 
malignant fibrous histiocytoma; %, percentage of tumors examined that are positive; Y, citations 
available online (http://www.vai.org/vari/metandcancer); N, no report (Ref.: Birchmeier et al., 
2003). 
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In addition, c-Met mutations in the JM domain have been reported in some cancer 
subtypes (Table 2)(Lee et al., 2000; Ma et al., 2003). Mutations in this domain prevent 
downregulation of c-Met and leads to extended c-Met signaling (Peschard et al., 2001). 
Therefore, a large number of studies show that HGF/SF, c-Met or both are frequently 
expressed in carcinomas, in other types of solid tumors, and in their metastases.  
 
The switch from a begnin to a malignant tumor includes a step where the tumor cells 
become more motile. Therefore, cell-cell junctions have to be disassembled. Fujita and 
colleagues recently described a possible way in which HGF/SF may contribute to this 
process. c-Met activation by its ligand mediates disruption of cell-cell contacts through 
the tyrosine phosphorylation-dependent binding of the SH2-containing E3-ubiquitin-
ligase Hakai to E-cadherin. Hakai then catalyzes the ubiquitination of the E-cadherin 
complex and enhances the subsequent E-cadherin endocytosis, resulting in a decrease 
of adherens junctions (Fujita et al., 2002). Accordingly, an inverse correlation between 
E-cadherin and c-Met has been reported in colon epithelial cells (Boon et al., 2005), 
further indicating the importance of this signaling cascade in tumorigenesis. 
The diverse set of cellular functions regulated by c-Met influence critical steps during 
the metastatic process including: (i) migration, secretion of proteolytic enzymes and 
invasive growth of tumor cell during extravasation, (ii) anoikis/survival of tumor cells in 
the vasculature, (iii) arrest in capillary beds and invasive infiltration of tumor cells to form 
micrometastases, and (iv) cell growth and survival at diverse remote microenvironments 
supporting the growth of micrometastases. In addition, the increased production of 
HGF/SF by tumor and stromal cells in neoplams at both primary and metastatic sites 
may affect the recruitment of endothelial cells and formation of microcapillaries during 
tumor neovascularization (see Figure 10). 
In conclusion, c-Met activation is not only a marker for cancer, but is also a marker of 
biological significance for malignancy. Especially in HCC, c-Met expression is correlated 
with increased incidence of intrahepatic metastasis and low patients’ 5-years survival 
rates (Ueki et al., 1997). Not surprisingly, HGF/SF and c-Met were therefore recently 
reported to be potential targets for chemotherapeutic intervention, highlighting their 
importance in tumor progression (Christensen et al., 2005; Corso et al., 2005; Jiang et 
al., 2005). 
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Figure 10: HGF/SF participates widely in the metastatic cascade. 
A primary breast tumor and its metastatic spread to the lung are depicted. HGF/SF has been 
reported to affect the following events: (1) disruption of cell adhesion mechanisms, including 
E-cadherin, claudins, and possibly desmosomes; (2) stimulation of secretion and/or activation 
of proteolytic enzymes that are involved in matrix degradation, including MMPs, uPA, etc.; (3) 
the stimulation of motility by HGF/SF can be seen throughout the metastatic process; (4) 
breach of the basement membrane (BM), as a result of increased proteolytic enzymes and 
HGF/SF-induced motility of cancer cells; (5) ‘the docking process’ that allows tumor cells to 
loosely connect to endothelial cells (EC); (6) ‘homing’ of cancer cells; (7) HGF/SF increases 
tumor adhesion to the endothelium, mediated by cell adhesion molecules, including CD44; (8) 
HGF/SF is known to affect and disrupt tight junctions, thus allowing increased paracellular 
permeability; (9) ‘extravasation process’; (10) division of adherent tumor cells followed by (11) 
formation of micro-emboli of tumor cells; (12) tumor emboli and embolism in microvessels 
which result in further disruption of the integrity of the endothelial monolayer and facilitate 
invasion of the endothelium by cancer cells; (13) HGF/SF acts as an angiogenic factor; and 
(14) promotes formation of metastatic tumors.  
F: fibroblasts; BM: basement membrane; EC: endothelial cells; (Jiang et al., 2005). 
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2 Aims of this study 
 
The hepatocyte growth factor/scatter factor (HGF/SF) has been implicated in numerous 
effects on tumor progression. Strikingly, increased levels of this growth factor were 
found in serum of patients with hepatoblastoma (HB) and hepatocellular carcinoma 
(HCC) after surgery, accompanied by increased growth of residual tumors, higher 
relapse incidence, and poor prognosis (von Schweinitz et al., 2000). A link between the 
high HGF/SF serum levels and the observed phenotype has been proposed. 
Comparative analysis of cell lines derived from different liver tumor subtypes could 
therefore help identifying general mechanisms by which HGF/SF promotes tumor 
progression. The general goal of this study was to unravel the molecular mechanisms 
underlying HGF/SF’s function in the oncogenic process. 
 
My studies at the Kantonsspital Basel and the Institute of Biochemistry and Genetics 
were aimed at characterizing in detail the effects of HGF/SF on HB and HCC growth, 
migration, survival, chemoresistance, and adhesion. Special consideration was given to 
the HGF/SF-induced signaling pathways underlying these cellular responses. 
 
The main objectives of this study were to: 
1.) investigate the role of HGF/SF on HB and HCC cell growth and progression, 
2.) characterize the anti-apoptotic effect of HGF/SF on HB and HCC cells, 
3.) unravel the molecular mechanisms which lead to HB and HCC cell scattering, 
migration, and invasion. 
 
Therefore, the investigations of the molecular pathways in HB and HCC cells should 
help to define more targets for therapeutic strategies and provide further insights into 
normal and aberrant liver development.  
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3 Materials and Methods 
3.1 Laboratory chemicals and biochemicals 
General chemicals used were all purchased from Sigma/Fluka (Buchs, Switzerland) 
unless otherwise stated. 
3.2 General maintenance of all cell lines  
All cell lines were cultured at 37°C, 95% humidity, and 5% CO2 in medium 
supplemented with 10% fetal calf serum (FCS, Sigma) and 2 mM glutamine (Invitrogen 
Basel, Switzerland). Prior to trypsinization, cells were washed once with 1x PBS (Sigma) 
to remove FCS. Cells were then detached with 1x trypsin/EDTA (Sigma). Hepatoma 
cells were maintained in RPMI1640 medium (Invitrogen), MDCK cells in Eagle’s 
minimum essential medium (MEM, Sigma), and HEK293 cells in Dulbecco’s modified 
Eagle’s medium (DMEM, Sigma). For long-term storage, cells were deep frozen (liquid 
N2) in 90% FCS, 10% DMSO. 
3.3 Cell lines 
3.3.1 HepT1 
This cell line was established from a multifocal, poorly differentiated hepatoblastoma 
of a 34-month-old girl. It has been characterized by immunohistochemistry, electron 
microscopy, and molecular genetic analysis in the laboratory of Prof. Torsten Pietsch 
(Pediatric Oncology, Institute for Neuropathology, University of Bonn) (Pietsch et al., 
1996). The HepT1 cell line has been injected into nude mice and the resulting tumors 
show hematopoietic foci similar to those observed in the original tumor (Pietsch et al., 
1996; von Schweinitz et al., 2000). 
3.3.2 HuH6 
This cell line was obtained through a biopsy from a hepatoblastoma of the right liver 
lobule of a one-year-old boy. These cells are strongly granulated and are positive for α-
fetoprotein, albumin and CK18 and CK19, and resemble the original tumors in this 
respect (Doi, 1976). This cell line is commercially available from the Japanese 
Collection of Research Bioresources (JCRB). 
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3.3.3 HepG2  
The liver epithelial HepG2 cell line is widely distributed and commonly used in 
research. It was originated from a liver biopsy of a 15-year-old Argentinean boy. This 
tumor is highly differentiated with trabecular cell order and positive for CKs, α-
fetoprotein, albumin, and plasminogen. Desmin and vimentin could not be detected in 
this cell line (Knowles et al., 1980). HepG2 is commercially available from the American 
Type Culture Collection (ATCC). 
3.3.4 MDCK 
Derived from a kidney of an apparently normal adult female cocker spaniel, the 
MDCK cell line was established by S. H. Madin and N. B. Darby (Gaush et al., 1966), 
and has been widely used for research. It is highly receptive for HGF/SF signals and 
therefore has often been used for investigations of HGF/SF-induced cellular responses. 
This cell line is commercially available from ATCC. 
3.3.5 HEK293 
The epithelial cell line HEK293 was generated by transformation of human embryonic 
kidney cell cultures (hence HEK) with sheared adenovirus 5’-DNA, and was first 
described in 1977 (Graham et al., 1977). Since then it has been commonly used and 
characterized in detail. This cell line is also commercially available from ATCC. 
 
3.4 DNA plasmid constructs 
For Snail promoter activation assays, a plasmid encoding for the mouse Snail 
promoter cloned upstream of a luciferase reporter was used (Peinado et al., 2003). For 
normalization, the luciferase reporter construct pRenilla (Promega) was co-transfected. 
To generate a construct expressing shRNA against Snail, Snail-shRNA 5'-
GATCCAGGCCTTCAACTGCAAATAGTGTGCTGTCCTATTTGCAGTTGAAGGCCTTTT
TTTGGAA-3' (forward) 5'-AGCTTTTCCAAAAAAAGGCCTTCAACTGCAAATAGGACA-
GCACACTATTTGCAGTTGAAGGCCTG-3' (reverse), and control-shRNA (mNCAM) 5’-
GATCCCCGTACAAGGCTGAGTGGAAGTTCAAGAGACTTCCACTCAGCCTTGTACT-
TTTTGGAAA-3’ (forward) and 5’-AGCTTTTCCAAAAAGTACAAGGCTGAGTGGA-
AGTCTCTTGAACTTCC-ACTCAGCCTTGTACGGG-3’ (reverse) oligonucleotides were 
annealed and inserted into the pSUPER-retro-puro vector according to the 
manufacture’s directions (OligoEngine, Seattle, WA, USA). 
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To create an inducible Snail 
expression system, a PCR 
fragment from the human 
constitutive active Snail-8SA 
cDNA (Figure 11, a gift from 
Dr. Mien-Chie Hung, University 
of Texas, Houston, USA) was 
generated using the following 
primers 5’-GCGCGGATCCA-
CCATGCCGCGCTCTTTCCT-
CG-3’ (forward) and 5’-CGCC-
GCTCGAGTCAGCGGGCA-
CATGGTGAG-3’ (reverse) and 
subcloned into the 
pcDNA5/FRT/TO vector at the 
BamH1 and Xho sites (per-
formed by F. Lehembre). 
For studying Egr-1-mediated transactivation, plasmids encoding for a dominant 
negative (dn) Egr-1-GST fusion protein (pEBGN-Egr-1), empty vector (pEBGN; (Al-
Sarraj et al., 2005)) or a Nab-resistant mutant of Egr-1 (pCMV-FLAG-C2/Egr-1; (Al-
Sarraj et al., 2005)) were used (all Egr-1 plasmids kindly provided by Dr. Gerald Thiel,  
 
Table 3: Plasmids used in this project.  
Plasmid name Insert Application 
pSUPER-RETRO-puro sh-hSnail ST 
pSUPER-RETRO-puro sh-mNCAM ST 
pMACS 4.1 CD4 TT, magnetic sorting 
pcDNA5/FRT/TO Snail-8SA TT, ST 
pCMV-FLAG-C2/Egr-1 FLAG-C2/Egr-1 TT 
pxp1 murine Snail promoter TT, luciferase assay 
pEBGN-Egr-1 dnEgr-1 TT, luciferase assay 
pEBGN empty vector TT, luciferase assay 
pRL-CMV Renilla luciferase TT, luciferase assay 
TT, transient transfection; ST, stable transfection. 
Figure 11: Snail sequence and mutation sites. 
A stabilized version of Snail was generated by site-specific 
mutations of GSK-3β binding sites, resulting in nuclear 
accumulation of Snail, which is constitutive-active (Zhou et 
al., 2004). 
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University of Saarland Medical Center, Homburg, Germany). An overview over all 
plasmids used in this study is provided in Table 3. 
 
3.5 Transfections and selection of transfected cells 
HepG2 cells were transiently transfected using Fugene (Roche Diagnostics, Basel, 
Switzerland) or the Amaxa Nucleofactor II device (program P-27, Amaxa, Cologne, 
Germany) according to the manufacturer’s instructions. 
pSUPER-Snail-shRNA and pSUPER-mNCAM-shRNA were transfected into HepG2 
cells using Fugene (Roche). Stable clones were obtained by selection with 150 µg/ml 
puromycin (Sigma) and were maintained under selection. Six out of 12 resistant clones 
were further analyzed and three showed reduced Snail mRNA levels. 
The inducible Snail-8SA construct was transfected into HEK293-FlpInTRex cells using 
Lipofectamine reagent (both Invitrogen). Stable clones were obtained after selection with 
hygromycin B and blasticidin (both Invitrogen), according to the manufacturer’s protocol. 
Snail-8SA-transfected HEK293-FlpInTRex cells were kept in FlpInTRex Medium (DMEM 
medium supplemented with 10% FCS, 2 mM glutamine, 15 µg/ml blasticidin, 100 µg/ml 
hygromycin B). Snail expression was induced by adding 1 µg/ml doxycycline (Sigma) to 
the culture medium. 
For transient transfection of HEK293 cells, Metafectene was used according to the 
manufacturer’s protocol (Biontex, Martinsried, Germany). 
 
3.6 Magnetic sorting of CD4-positive HepG2 cells 
HepG2 cells were transiently co-transfected with the eukaryotic vector pMACS 4.1 
(Miltenyi Biotec, Bergisch Gladbach, Germany) encoding for a truncated, human CD4 
cell surface receptor, incapable of inducing CD4-mediated signal transduction. After 
electroporation using the P-27 program of the Amaxa Nucleofector II device, cells were 
allowed to recover for three days. Cells were harvested with 2 mM EDTA in PBS and the 
cell suspension was mixed with MACS CD4 MicroBeads (Miltenyi Biotec) for magnetic 
labeling. Magnetic separation was performed by applying the labeled cells onto a MS 
column attached to an OctoMACS separator according to the instructions of the 
manufacturer (both Miltenyi Biotec). Positively selected cells were recultured for 48 h 
and then stimulated with 10 ng/ml HGF/SF for 8 h. Total RNA was isolated with the 
Trizol method according to the manufacturer’s protocol (Invitrogen).  
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For Snail promoter activation assays (Peinado et al., 2003), HEK293 cells in 24-well 
plates were transiently transfected at about 70% confluency with a total of 2 to 4 µg 
plasmid DNA by using Metafectene (Biontex, Martinsried, Germany) in a ratio to DNA of 
2:1. Cells were incubated with DNA/Metafectene complexes for 24 h in normal medium 
at 37°C before lysis. 
 
3.7 Immunoblot analysis 
Cells were seeded in cell culture dishes of appropriate size and incubated with growth 
factors or inhibitors as indicated. After removal of the medium and two washing steps 
with ice-cold PBS, cells were lysed in RIPA+ buffer (50 mM Tris-HCl (pH 8.0), 150 mM 
NaCl, 10% glycerol, 1% NP40, 0.5% sodium deoxycholate (DOC), 0.1% sodium dodecyl 
sulfate (SDS), 2 mM CaCl2, 2 mM MgCl2, and freshly added 1 mM dithiotreitol (DTT), 
1 mM sodium fluoride (NaF), 0.1 mM phenyl methyl sulfonyl fluoride (PMSF), 2 mM 
sodium orthovanadate (Na3VO4), and 1x protease inhibitor cocktail (Sigma)) and kept for 
30 min on ice. After centrifuging at 12,000 x g for 10 min at 4°C, supernatant was frozen 
until subjected to analysis. Protein concentration was determined on a BioPhotometer 
(Vaudaux-Eppendorf, Schönenbuch, Switzerland) by utilizing the BioRad Protein Assay 
(BioRad, Reinach, Switzerland). 50 µg of cell lysates were boiled in Laemmli buffer 
(Laemmli, 1970), resolved by sodium dodecylsulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) and proteins were transferred to an Immobilon P PVDF membrane 
(Millipore, Volketswil, Switzerland). Membranes were blocked with 5% non-fat milk in 
TBS (35 mM Tris-HCl (pH 7.4), 140 mM NaCl) containing 0.05% Tween-20. After 
primary and HRP-conjugated secondary antibody incubation (see Table 4 for antibodies 
used), ECL+ (Amersham Biosciences, Freiburg, Germany) or UptiLight (Interchim, 
Montluçon, France) were used for chemiluminescence detection of protein bands on 
superRX films (Fuji, Dielsdorf, Switzerland).  
 
 Table 4: Antibodies used for immunoblotting 
Name Source Dilution Company 
HGF/SF mouse 1:1000 R&D Systems 
c-Met mouse 1:1000 Cell Signaling Technology 
p-Met (Tyr1349) rabbit 1:1000 Cell Signaling Technology 
p-p-Met (Tyr1234/1235) rabbit 1:1000 Cell Signaling Technology 
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p-Akt rabbit 1:1000 Cell Signaling Technology 
Akt rabbit 1:1000 Cell Signaling Technology 
p-GSK-3β rabbit 1:1000 Cell Signaling Technology 
GSK rabbit 1:1000 Cell Signaling Technology 
E-cadherin mouse 1:2000 BD Transduction Lab 
β-catenin rabbit 1:2000 Sigma 
hSnail, N-term rabbit 1:400 Abgent 
p-ERK-1/2 mouse 1:1000 Cell Signaling Technology 
ERK-1/2 rabbit 1:1000 Cell Signaling Technology 
β-actin mouse 1:5000 Abcam 
Vinculin goat 1:1000 Santa Cruz Biotechnology 
Egr-1 rabbit 1:500 Santa Cruz Biotechnology 
p-STAT3 rabbit 1:1000 Cell Signaling Technology 
STAT3 rabbit 1:1000 Cell Signaling Technology 
p-STAT1 rabbit 1:1000 Cell Signaling Technology 
STAT1 rabbit 1:1000 Cell Signaling Technology 
anti-mouse-IgG goat 1:5000 SouthernBiotech 
anti-rabbit-IgG goat 
1:5000 – 
1:10000 
Transduction Labs 
anti-goat-IgG donkey 1:1000 Jackson ImmunoResearch 
Abbreviation: p-, phospho-specific 
 
3.8 MTT Assay 
To assess cell viability, 100 µl pre-warmed MTT solution (5 mg/ml in PBS) was added 
to 1 ml of culture medium. After 1 h incubation, the medium was aspirated and 500 µl of 
solubilisation buffer (95% isopropanol, 5% formic acid) were added per 24-well. Then, 
the plate was transferred to a horizontal shaker for homogenization of the cell lysate. 
100 µl of each sample were transferred to a 96-well microtiter plate (Becton Dickinson) 
and measured in a SpectraMax 340PC (Molecular Devices) at 560 nm.  
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3.9 3[H]-Tymidine incorporation 
Stimulated cells were kept in growth and stimulation medium before 1 µCi/ml [3H]-
thymidine (Amersham) was added to each well. After 3 h incubation, incorporation was 
terminated by careful washing of the cells twice with 1 ml ice cold PBS and 1 ml of ice 
cold 5% TCA. The cells were then incubated for 30 min at 4°C before being washed 
once with ice cold PBS. At room temperature (RT), cells were then solubilized in 0.5 ml 
0.5 N NaOH/0.5% SDS. Lysates were mixed by pipetting up and down and added to 
scintillation vials. After the scintillation cocktail (Ready Safe) was added, the samples 
were measured with a LS 6500 Liquid Scintillation Counter (both Beckman Coulter, 
Nyon, Switzerland). 
 
3.10 Cell proliferation/ Cytometry 
Cells were seeded in duplicate at 5 × 105 cells/ well in 24-well plates. The next day, 
the cells were stimulated with various HGF/SF concentrations and incubated for the 
indicated time. Cells were then trypsinized in 1 ml trypsin/EDTA and 100 µl of the cell 
suspension was diluted with 10 ml Isoton II (Beckman Coulter). They were then counted 
with a Coulter Counter with particle size set between 8 and 12 µm. 
 
3.11 Preparation of nuclear extracts 
Stimulated cells were washed twice with ice-cold PBS and lysed in Low Salt buffer 
(20 mM Hepes (pH 7.9), 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 0.2% NP40, 10% 
glycerol, 0.1 mM Na3VO4, 1 mM PMSF, 1 mM DTT, 2 µg/ml aprotinin, 1 µg/ml leupeptin). 
After 10 min on ice, cell lysates were centrifuged at 3,000 x g for 5 min at 4°C). 
Supernatants were transferred to new Eppendorf tubes and used as cytosolic extracts. 
The remaining pellets were lysed in High Salt buffer (420 mM NaCl, 20 mM Hepes 
(pH 7.9), 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 20% glycerol, 0.1 mM Na3VO4, 1 mM 
PMSF, 1 mM DTT, 2 µg/ml aprotinin, 1 µg/ml leupeptin) and incubated for 30 min on ice 
with intermittent vortexing. Samples were cleared by centrifugation for 5 min at 
12,000 x g at 4°C, and supernatants were aliquoted, shock frozen on dry ice and stored 
at -80°C.  
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3.12 Electrophoretic Mobility Shift Assay (EMSA) 
For the binding reaction, nuclear extracts (2 µl, 5 – 10 ng protein) were incubated at 
room temperature in 5x shift buffer (20 mM Hepes (pH 7.9)), 4% Ficoll, 1 mM MgCl2, 
40 mM KCl, 0.1 mM EGTA, 0.5 mM DTT, 160 µg/ml poly [dI-dC] (Roche)) with 1 ng 32P-
ATP-labeled oligonucleotides (>105 cpm) for 20 – 30 min at room temperature.  
Nucleoprotein-oligonucleotide complexes were resolved by a 5% non-denaturing 
PAGE at 400 V for 4 h at 4°C. Gels were dried for 1 h at 80°C, and exposed overnight at 
RT to Storage Phosphor Screens (Amersham Biosciences, Freiburg, Germany). Results 
were then digitized using a phosphor imaging system (PhosphorImager) and quantified 
by ImageQuant software (both Amersham Biosciences). The following oligonucleotides, 
corresponding to STAT-response-element sequences were used: mutated serum-
inducible element (SIE-m67) = 5’ CATTTCCCGTAAATCAT-3’; βCas = 5’-
GATTTCTAGGAATTCAATCC-3’ (Fasler-Kan et al., 1998). The specificity of the DNA-
protein complex was confirmed by adding 1 µl 1:10-diluted specific STAT antibodies 
(STAT1, sc346; STAT5, sc1656; STAT6, sc621; Santa Cruz Biotechnology) to the 
incubation mix, resulting in a stronger retention of the complex (‘supershift’). 
 
3.13 Caspase 3-like protease activity 
After incubation with the apoptotic inducers in the presence or absence of HGF/SF for 
the indicated time points, cells were washed three times with PBS and lysed with 
hypotonic extraction buffer (25 mM HEPES (pH 7.5), 5 mM MgCl2, 1 mM EGTA, 1 mM 
Pefabloc, pepstatin, leupeptin and aprotinin (1 mg/ml each), and 0.1% Triton X-100). All 
lysates were cleared by centrifugation (15 min, 13,000 g, 4°C), and supernatants were 
frozen immediately and stored at -80°C until measurement.  
The cleavage assay was carried out on opaque microtiter plates (DynaStar, Dynatech, 
Chantilly, USA) according to the method originally described by Thornberry (Thornberry 
and Lazebnik, 1998); generation of free 7-amino-4-trifluoromethylcoumarin (afc) was 
measured in assay buffer (50 mM HEPES (pH 7.4), 1% sucrose, 0.1% CHAPS, 10 mM 
– 25 mM DTT, and 50 µM fluorogenic substrate N-acetyl-asp-glu-val-asp-afc) after 
120 min at 37°C using a microplate fluorometer SpectraMax Gemini EM (Molecular 
Devices) set to an excitation wavelength of 395 nm and an emission wavelength of 
505 nm. Protein concentrations of corresponding samples were quantified with the 
BioRad protein assay (BioRad), and the specific caspase-3-like activity was calculated 
after 120 min as relative fluorescence units (FLU) per mg protein. 
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3.14 Cell scattering 
Cells were seeded in 12-well tissue culture dishes at a density of 1x105 per well. 24 h 
later, cells were incubated with HGF/SF (5 to 20 ng/ml) or PBS. When inhibitors were 
used, cells were pre-incubated with inhibitors for 1 h before addition of HGF/SF. Control 
cells were treated with 1 µl/ml DMSO. After 72 h, phase-contrast pictures were taken 
with a Nikon COOLPIX 995 (Egg/ZH, Switzerland) camera attached to a Leitz Labovert 
FS microscope (Leica, Heerbrugg, Switzerland). 
 
3.15 Isolation of total RNA 
Total RNA was isolated using Trizol reagent according to the manufacturer’s 
instruction (Invitrogen). Shortly, subconfluent cell layers on 60-mm cell culture dishes 
were washed in 1x PBS and subsequently 1 ml of Trizol was added. After an incubation 
and centrifugation step, chloroform was added and after vigorous mixing shortly 
incubated. After phase separation, the upper RNA-containing aqueous phase then was 
transferred to a fresh Eppendorf tube and 0.5 ml isopropanol added. Precipitated RNA 
was washed with 1 ml of 75% ethanol and finally centrifuged at 7,500 x g at 4°C for 
5 min. Pelleted RNA was air-dried completely and dissolved in diethylpyrocarbonate 
(DEPC)-treated deionized water (DEPC-H2O). Before freezing, dissolved RNA was 
incubated for 10 min at 60°C. 
 
3.16 Quantitative SYBR green real time RT-PCR (qPCR) 
Total RNA (3 µg) was reverse transcribed with random hexamer primers using M-
MLV reverse transcriptase RNAse (H-) (Promega, Wallisellen, Switzerland). To verify 
that the primers did not amplify genomic DNA, RNA samples were also incubated in the 
absence of the reverse transcriptase (-RT samples). Transcripts of various genes were 
detected by quantitative SYBR green RT-PCR (qRT-PCR) on an ABI Prism 7000 
TaqMan using the SYBR green PCR MasterMix (both Applied Biosystems, Rotkreuz, 
Switzerland) with the primers listed in Table 5. Each PCR mixture contained cDNA, 
SYBR green MasterMix, and 300 nM primer pair in a final volume of 25 µl. The PCR 
conditions were an initial denaturation step of 2 min at 50°C and 10 min at 95°C, 
followed by 40 cycles consisting of 15 sec at 95°C, and 1 min at 60°C. PCR assays 
were performed in triplicates and relative mRNA expression was calculated of the mean 
value with the comparative Ct method (ΔΔ Ct) (Yuan et al., 2006). 
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Table 5: Oligonucleotides used for qRT-PCR and qPCR 
Name forward primer reverse primer Application 
Slug 5-GGACACATTAGAACTCACACGGG-3’ 5’-GCAGTGAGGGCAAGAAAAAGG-3’ qRT-PCR 
Twist 5-GCAGGGCCGGAGACCTAG-3’ 5’-TGTCCATTTTCTCCTTCTCTGGA-3’ qRT-PCR 
hSnail 5’-CACTATGCCGCGCTCTTTC-3’ 5’-CACTATGCCGCGCTCTTTC-3’ qRT-PCR 
h3’UTR-
Snail 
5’-TCCCGGGCAATTTAACAATG-3’ 5’-TGGGAGACACATCGGTCAGA-3’ qRT-PCR 
canine 
Snail 
5’-TTGCCGACCGCTCCAA-3’ 5’-CAGGG-ACATGCGGGAGAA-3’ qRT-PCR 
canine 
β-actin 
5’-ACGTTGACATCCGCAAGGAC-3’ 5’-CAGGGCAGTGATCTCCTTCTG-3’ qRT-PCR 
hRPL19 5’-GATGCCGGAAAAACACCTTG-3’ 5’-CAGGGCAGTGATCTCCTTCTG-3’ qRT-PCR 
Egr-1 5’-ACCGCAGAGTCTTTTCCTGACA-3’ 5’-TCGAGTGGTTTGGCTGGG-3 qRT-PCR 
Claudin-3 5’- CAGCAACATCATCACGTCGC-3’ 5’- CAGTTCATCCACAGGCCCTC-3’ qRT-PCR 
Snail 5’-TCGCTTCCTCCCCAGTGAT-3’ 5’-TGGAGAGCGTGGCATTGAC-3’ qPCR 
NCAM 5’-GTTCCATCAAAACGAACGAACCCG-3’ 5’-CACTCGCAACTCGGAGATCC-3’ qPCR 
 
3.17 Reporter gene assays 
By using the Amaxa Nucleofactor II device, cells were transiently transfected with a 
mouse-Snail promoter cloned upstream of a firefly luciferase reporter (Peinado et al., 
2003). For normalization, the luciferase reporter construct pRenilla (Promega) was co-
transfected. After transfection, cells were allowed to recover for 24 h and then incubated 
with 10 ng/ml HGF/SF or 2 mM LiCl. 
Dual-Luciferase reporter (DLR) assays were performed in duplicate according to the 
directions of the manufacturer (Promega). Cells were lysed in passive lysis buffer and 
transferred to an opaque 96-well assay plate. Light units generated by both luciferase 
activities were recorded with a Berthold Mithras LB 940 luminometer (Berthold 
Technologies, Regensdorf, Switzerland). Luciferase activities were expressed as 
relative light units (RLU). Firefly luciferase activities (LAR) were always normalized to 
the control Renilla luciferase activity (RAR). 
 
3.18 Chromatin immunoprecipitation (ChIP) analysis 
The ChIP assay was performed using the ChIP assay kit (Upstate Biotechnology, 
Lucerne, Switzerland) following the instructions provided by the manufacturer. Shortly, 
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after stimulation with HGF/SF, histones were cross-linked to DNA for 10 min by adding 
formaldehyde to a final concentration of 1% to the medium. After two washing steps with 
ice-cold PBS containing protease inhibitors (1 mM PMSF, 1 µg/ml aprotinin and 1 µg/ml 
pepstatin A), cells were scraped off the plate and lysed in SDS lysis buffer for 10 min on 
ice. Cell lysates were sonicated five times with 10 sec pulses at 30% of maximum power 
with samples kept on ice during the whole procedure to shear DNA into fragments of 
200 – 1000 bp length.  
Sonicated cell suspension were then diluted in 10x ChIP dilution buffer (Upstate) 
containing protease inhibitors mentioned afore. For reduction of the background, 75 µl 
protein A agarose/salmon sperm DNA were added for 30 min at 4°C and kept under 
agitation. After removal of the protein A agarose/salmon sperm DNA, rabbit anti-Egr-1 
(sc-189), rabbit anti-Snail (Abgent) in a concentration of 10 µg/ml each or unrelated 
rabbit IgG were used to immunoprecipitate DNA-containing complexes overnight. To 
collect the antibody/histone complex, 60 µl protein A agarose/salmon sperm DNA were 
added for 1 h and kept under agitation for 1 h at 4°C. Afterwards serial washing with 
Low Salt buffer, High Salt buffer, and LiCl immune complex wash buffer (all Upstate) 
were performed to remove unbound non-specific DNA. For the subsequent PCR, 
histone complexes were eluted from the antibody by addition of 250 µl elution buffer to 
the pelleted protein A agarose/antibody/histone complex. After incubation for 15 min at 
RT under agitation, the agarose was spun down, and the supernatant-containing DNA 
was mixed with 5 M NaCl and incubated for 4 h at 65°C to reverse cross-link histones to 
the DNA. Next, 10 µl 0.5 M EDTA, 20 µl 1 M Tris-HCl and 2 µl of 10 mg/ml proteinase K 
were added to the eluates and incubated for 1 h at 45°C. DNA was then recovered by 
phenol/chloroform extraction and ethanol precipitation. Pellets were washed with 70% 
ethanol and air-dried. 
PCR was performed with primers 5'-GTTTCCCTCGTCAATGCCACGCTC-3' (forward) 
and 5'-CGTGCCGCGGCGCAATGAATGCAGC-3' (reverse) complementary to the Snail 
promoter region containing Egr-1 binding sites and primers 5’-TTTCGG-
ATTCCCGCAGTGTGG-3’ (forward) and 5’-TAGGAAGTCACGGCCACTTGG-3’ 
(reverse) complementary to the E-box containing region of the Egr-1 promoter, 
respectively. DNA samples were analyzed by 2% agarose gel with ethidium bromide 
staining. This analysis was performed by F. Lehembre. 
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3.19 Immunofluorescence 
Cells were grown on uncoated glass cover slips and washed twice with HEPES-
buffered saline (HBS; 1  HEPES, 10 mM HEPES (pH 7.4), 150 mM NaCl, 3 mM EDTA, 
2 mM CaCl2, 2 mM MgCl2) before fixation in 4% paraformaldehyde in HBS for 20 min at 
RT. Cells were washed three times in HBS, permeabilized with 0.3% Triton X-100 in 
HBS for 10 min at RT, before they were washed three times in HBS. After blocking cells 
for 30 min with 3% bovine serum albumin (BSA) in HBS, primary antibodies in 3% BSA, 
in HBS were added (1 h at RT). Cells were washed three times in HBS, then secondary 
antibodies conjugated with different fluorochromes (Alexa Fluor 546, 568, 488 from 
various species (Molecular Probes)) were added (1 h at RT) in the dark. After washing 
the cells three times with 0.05% Tween-20, 0.1% BSA in HBS, 4',6-Diamidino-2-
phenylindole (DAPI) (1 mg/ml) was added for 1 to 3 min in the dark, followed by two 
washing steps with HBS and one final washing step with deionized H2O before the cover 
slips were mounted on glass slides with the fluorescent mounting medium Mowiol (12% 
glycerine, 4.8% Mowiol, 24% 0.2 M Tris-HCl (pH 8,5), 0,1% DABCO). 
 
Table 6: Antibodies used for immunofluorescence stainings in this study 
Name Source Dilution Company 
p-STAT1 rabbit 1:100 Cell Signaling Technology 
p-STAT3 rabbit 1:100 Cell Signaling Technology 
Anti-mouse-IgG-488 rabbit 1:600 Molecular Probes 
Anti-mouse-IgG-546 rabbit 1:600 Molecular Probes 
Anti-rabbit-IgG-488 goat 1:600 Molecular Probes 
Anti-rabbit-IgG-546 goat 1:600 Molecular Probes 
Cytokeratin 8 rabbit 1:250 Abcam 
Cytokeratin 18 rabbit 1:250 Abcam 
Cy3-conjugated anti-
rabbit 
goat 1:200 Jackson ImmunoResearch 
Cy8-conjugated anti-
rabbit 
goat 1:200 Jackson ImmunoResearch 
Abbreviation: p-, phospho-specific 
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3.20 Statistical analysis 
Student’s t-test was used to compare data between two groups. Values are expressed 
as mean ± standard deviation (SD) of at least triplicate measurements. Statistical analysis 
was performed using GraphPad Prism 4.0c (GraphPad Software, San Diego, USA). P-
values < 0.05 were considered statistically significant. 
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4 Results 
In HB and HCC patients, markedly elevated serum levels of HGF/SF are frequently 
found. HGF/SF, the ligand for the receptor tyrosine kinase c-Met, is a multipotent factor 
that regulates cell growth, motility, invasion, angiogenesis, and morphogenesis of 
various cells types. Especially during organogenesis and regeneration, it mediates 
crucial facets and seems to be a key modulator of epithelium-mesenchyme interactions. 
The aim of this study was to analyze the importance of this factor in HB and HCC 
progression. 
 
4.1 HGF/SF as a mitogen for HB and HCC cells 
HGF/SF induces cell proliferation in many cell types, thereby acting as a mitogen 
(Weidner et al., 1993). This study aimed to investigate whether HGF/SF might promote 
HB and HCC cell proliferation. For this purpose HGF/SF’s potential mitogenic activity 
was assessed by [3H]-thymidine incorporation, cell counts, and MTT viability assays. 
 
4.1.1 [3H]-Thymidine incorporation 
To quantitate the DNA synthesis rate after HGF/SF stimulation in comparison to 
untreated cells, HB (HuH6, HepT1) and HCC (HepG2) cells were incubated with 
various amounts of HGF/SF in normal growth medium for 48 h. Afterwards cells were 
harvested and [3H]-thymidine incorporation was determined by liquid scintillation. 
HGF/SF incubation did not result in an increase of total [3H]-thymidine incorporation in 
any of the cell lines tested (Figure 12, blue bars). The total cell number (Figure 12, red 
bars) was not significantly different in comparison to those of untreated cells. The ratio 
of incorporated [3H]-thymidine per cell as a marker for DNA synthesis rate neither was 
changed (Figure 12, yellow bars), suggesting that HGF/SF does not have a mitogenic 
effect on human HB and HCC cell lines. 
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Figure 12: DNA synthesis rates in HB and HCC cells. [3H]-thymidine incorporation and 
total cell numbers were assessed after incubation with various HGF/SF concentrations for 
48 h. Values represent percent of control. Blue bars, cell number relative to control; red 
bars, total decays per minute (DPM) relative to control, yellow bars, DPM per cell relative to 
control. 
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Figure 13: Growth curves of HB and HCC cell lines. Cells were cultured in the absence or 
presence of different HGF/SF concentrations and measured by the MTT assay at the time 
points indicated. 
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4.1.2 Cell viability 
To check whether HGF/SF could affect long-term growth behavior, growth curves of 
the HB and HCC cell lines were generated for a time period of 8 days. Cells were grown 
in normal growth medium and incubated in the presence or absence of various HGF/SF 
concentrations. Cell viability was analyzed daily by the MTT method (Figure 13). Again, 
the presence of HGF/SF did not alter the growth rate of HB and HCC cells in 
comparison to untreated control cells.  
As a positive control, MDCK cells, which are known to be receptive to HGF/SF signals 
(Weidner et al., 1993), were treated with the same batch of human recombinant 
HGF/SF. Here, increased cell proliferation and the scattering phenotype were observed, 
indicating that the HGF/SF used was properly functional (data not shown). In 
conclusion, these experiments show that HGF/SF does not act as a proliferative factor 
for HB and HCC cells. 
 
4.2 Integrity of the signal transduction pathways 
Since the HGF/SF used showed full biological activity, it was speculated that 
disturbances of the signal transduction pathways downstream of the c-Met receptor in 
HB and HCC cells might explain the observed insensitivity towards growth stimulation. 
Thus, the activated pathways were investigated in detail by using specific antibodies 
against phosphorylated forms of downstream kinases and by performing electrophoretic 
mobility shift assays (EMSAs) on STAT protein targets. 
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4.2.1 Phosphorylation of the c-Met receptor 
  
Binding of HGF/SF leads to the phosphorylation of its receptor c-Met (Weidner et al., 
1993). To check whether this phosphorylation takes place in HB and HCC cells as well, 
cells were incubated with different amounts of HGF/SF in normal growth medium for 
30 min. Afterwards, cells were lysed and subjected to immunoblot analysis with 
antibodies specific for tyrosine residues Y1234/35-phosphorylated c-Met and total Met 
(Figure 14). Immunoblot analysis revealed that HB and HCC cell stimulation with 
HGF/SF triggered autophosphorylation of the c-Met receptor. Further, it was detected 
that the total amount of c-Met protein present in the HB cell lines HepT1 and HuH6 is 
lower than in HepG2 and HEK293 cells. Accordingly, those cell lines showed weaker 
c-Met phosphorylation upon HGF/SF stimulation. 
Also, conditioned medium from foreskin fibroblasts (FS-Fb-c Me) as a possible 
natural source of HGF/SF was included in this study. However, this medium was not 
sufficient to induce c-Met phosphorylation in all cell line tested, suggesting none or low 
amounts of HGF/SF present. 
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Figure 14: Phosphorylation status of the c-Met receptor. HB and HCC cells and for comparison, 
HEK293 cell were treated with various concentrations of HGF/SF and foreskin fibroblasts-conditioned 
medium (FS-Fb-c Me) for 30 min. After lysis, cells were subjected to immunoblot analysis with antibodies 
specific for tyrosine phosphorylated c-Met and total c-Met. Marker sizes are given in kDa. 
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4.2.2 Sustained phosphorylation of Akt/PKB 
 As mentioned above, PI3K is activated by HGF/SF signaling, which in turn 
phosphorylates Akt/PKB. To check whether HGF/SF stimulation is sufficient to activate 
Akt/PKB in HB and HCC cells, immunoblot analysis with antibodies specific for the 
phosphorylated form of this kinase was performed on lysates from cells treated with 
HGF/SF for different time points (Figure 15). Interestingly, HuH6 showed an increasing 
phosphorylation of Akt/PKB with time and peaked after 60 min. Similarly, Akt/PKB 
phosphorylation in HepT1 cells was the strongest after 60 min and declined afterwards. 
In contrast, the HCC cell line HepG2 showed increasing Akt/PKB phosphorylation 
levels, which were not yet reduced after 120 min. These immunoblots demonstrate that 
Akt/PKB is rapidly (within 15 min) and sustainably (for at least up to 2 h) phosphorylated 
upon HGF/SF treatment in all cell lines tested. 
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Figure 15: HGF/SF-induced phosphorylation of Akt/PKB in HB and HCC cells. 
Cells were incubated with 10 ng/ml HGF/SF for the time points indicated. After lysis, 
cells were subjected to immunoblotting with specific antibodies against phospho-Akt 
and β-actin. 
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4.2.3 Activation of MAPK/ERK-1/2 pathway 
 Numerous previous studies have shown that many HGF/SF-induced cellular 
responses are mediated through the activation of the p42/p44 MAPK (also called ERK-
1/2) and hereby also plays a pivotal role in tumorigenesis (Birchmeier et al., 2003). 
Therefore, the MAPK activation induced by HGF/SF stimulation was investigated in HB 
and HCC cells by immunoblotting (Figure 16).  
 Indeed, when these cell lines were treated with different amounts of HGF/SF, 
phosphorylation of ERK-1/2 was clearly detectable. 10 ng/ml HGF/SF is already 
sufficient to induce ERK-1/2 phosphorylation within 30 min, which is not gradable with 
higher HGF/SF concentrations. Notably, the phosphorylation of MAPK/ERK-1/2 in HuH6 
cells is modest in comparison to the HepT1 and HepG2 cells, which could be due to 
lesser c-Met phosphorylation as discussed above. 
 
4.2.4 Activation of the Jak/STAT pathway 
Many stimuli lead to STAT activation other than cytokine stimuli, including growth 
factors that use tyrosine kinase receptors (Aaronson and Horvath, 2002). For example, 
STAT3 is directly activated by many cytokines that use signaling receptor subunits 
similar to cytokine receptor gp130 (Ishihara and Hirano, 2002). Activation of STAT3 
occurs in many solid and hematologic tumors and is correlated with growth stimulation 
and anti-apoptotic effects in malignancies (Bowman et al., 2000). In addition, STAT3 is 
activated by the cellular non-receptor tyrosine kinase, c-Src. This is a striking example 
Figure 16: HGF/SF-induced phosphorylation of Akt/PKB in HB and HCC cells. Cells were 
treated with different concentrations of HGF/SF for 30 min. After cell lysis, immunoblot analyses with 
an antibody specific against phosphorylated ERK-1/2 were performed. 
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of cross-talk and interconnection between functionally and conceptually distinct 
signaling pathways through a cellular proto-oncogene (Aaronson and Horvath, 2002). 
To date little is known about a STAT involvement in transducing HGF/SF signals in 
HB cells. Therefore, the activation of this pathway in HB and HCC cells upon growth 
factor and cytokine stimulation, including IL-4, IL-6, IFN-α, IFN-γ, EGF, stem cell factor 
(SCF), and HGF/SF was analyzed. As a positive control, the Wilms’ tumor cell line 
SKNEP and the B cell lymphoma cell line Daudi were included in this study (Figure 17 
and Figure 18). 
Cells treated with various cytokines and growth factors for different time points were 
lysed and fractionated. The nuclear fractions containing the STAT proteins bound to 
DNA were mixed with 32P-radiolabeled oligonucleotides, corresponding to STAT-
response element sequences: mutated serum-inducible element (SIE-m67) and 
β-casein (βCas). By non-denaturating PAGE, the DNA/protein complexes were 
separated according to their molecular weight. For supershift experiments, specific 
antibodies against the corresponding STAT protein were added, resulting in the 
formation of a larger complex that migrated slower through the gel. For visualization, 
gels were dried and exposed to a PhosphorImager screen. 
When the SIE-m67 probe was used, STAT1 homodimers in Daudi cells as well as 
the STAT1 and STAT3 homo- and heterodimers in SKNEP cells could be detected 
within 20 min of IL-6 stimulation (Figure 17). Also HepT1, HepG2 and to a lesser extend 
HuH6 cells did respond to IL-6 treatment by activating STAT1. In HepG2 STAT1:3 
heterodimers could additionally be detected. In contrast, HGF/SF treatment did not 
result in STAT1 or STAT3 phosphorylation (data not shown) and subsequent binding to 
DNA (Figure 17).  
In the experiments where the βCas probe was used, the Daudi cell line clearly 
showed STAT1, STAT5, and STAT6 homodimers, as well as STAT5:6 heterodimers 
upon IFN-α treatment (Figure 18). When HB and HCC cells were treated with IL-4 for 
20 min, activation of STAT6 was determined. By the addition of an antibody against 
STAT6, the DNA/protein complex was supershifted, suggesting specific binding of 
STAT6 to the βCas probe. However, when cells were stimulated with HGF/SF for 
various time periods, no induction of STAT1, STAT5, or STAT6 were detected by EMSA 
analysis, suggesting that this pathway plays no or only a minor role in HGF/c-Met signal 
transduction (Figure 18). Interestingly, a small band at the height of STAT5 was 
observed in all HB and HCC cells, raising the question whether a constitutive activation 
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of STAT5 is present in these cells and whether this could contribute to increased cell 
proliferation. 
 
 
 
 
 
 
Figure 17: STAT1 and STAT3 phosphorylation and subsequent 
binding to radiolabled probes. Upon growth factor and cytokine 
stimulation STAT protein binding to DNA was analyzed by EMSA 
with the SIE-m67 probe in HB, HCC, B cell lymphoma Daudi, and 
Wilms’ tumor SKNEP cell lines. 
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Figure 18: STAT1, STAT5, and STAT6 phosphorylation and subsequent binding to 
radiolabeled probes. Upon growth factor and cytokine stimulation STAT protein binding to DNA 
was analyzed by EMSA with the βCas probe in HB, HCC, Wilms’ tumor SKNEP, and B cell 
lymphoma Daudi cell lines. 
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To test STAT activation by another assay system, translocations of phosphorylated 
STAT proteins to the nucleus were visualized by immunofluorescence staining. After 
IFN-γ treatment, cells were fixed and stained with antibodies specific for phosphorylated 
STAT proteins. Nuclear localization of phosphorylated STAT1 proteins could be 
detected upon IFN-γ treatment in HepT1 cells (Figure 19), but also in HuH6 and HepG2 
cells (data not shown). However, no nuclear localization of STAT proteins were detected 
after HGF/SF, EGF, and SCF stimulation (data not shown). 
 
Table 7: Summary of EMSA results 
Cell line 
GF, cytokine 
HepT1 HuH6 HepG2 
INF-α - - STAT1 
IFN-γ STAT1 STAT1 STAT1 
IL-4 STAT6 STAT6 STAT6 
IL-6 STAT1 STAT1 STAT1, STAT3 
EGF - - - 
HGF - - - 
SCF - - - 
 
 
 B C 
 
A 
 
Figure 19: Immunofluorescence stainings of HepT1 cells. 
(A) unstimulated: negative STAT1 staining in nuclei, (B) unstimulated, Hoechst and cytokeratin 
18 staining, (C) nuclear localization of phosphorylated STAT1 after IFN-γ stimulation (500 U/ml) 
for 20 min and staining of cytoplasmic cytokeratin 18. 
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In summary, these results show that IFN-γ activates STAT1 in HB and HCC cells 
whereas IFN-α activates STAT1 in HepG2 cells only. IL-6 was capable of activating 
STAT1 (and STAT3 in HepG2), and IL-4 activated STAT6 in all cell lines investigated. 
This indicates that the Jak/STAT pathway is functional in these cell lines. Upon stimu-
lation of the cells with various HGF/SF, EGF or SCF concentrations for different time 
periods, no STAT activation could be detected, suggesting that these growth factors do 
not activate the Jak/STAT pathway in these cells. 
 
From these experiments it appears that the functional integrity of pathways important for 
cell proliferation is given and that either these cells have lost their responsiveness to 
external growth stimulation, or other factors are responsible for HGF/SF not being able of 
inducing cell growth, e.g. culture conditions, the absence of the appropriate extracellular 
matrix or cell intrinsic growth stimulation. 
 
4.3 HGF/SF as an anti-apoptotic factor 
It was previously shown that HGF/SF also plays a pivotal role in inhibition of apoptosis 
(Fan et al., 2000; Liu, 1999). Evasion from apoptosis is another key feature of tumor 
progression (Hanahan and Weinberg, 2000). Since many HB and HCC are resistant to 
chemotherapy, this resistance could be mediated by the presence of high HGF/SF 
levels that are frequently found. 
To test the hypothesis whether HGF/SF is capable of preventing apoptosis in HB and 
HCC cells, thus leading to a higher survival rates of the tumor cells, apoptosis was 
induced with various known apoptosis inducers in the presence of absence of HGF/SF. 
Apoptosis was assessed using a fluorogenic DEVD-afc cleavage assay that measures 
caspase 3-like activity in the cells (Thornberry and Lazebnik, 1998). 
 
4.3.1 Cisplatin 
Cisplatin (CP) is used as standard treatment for many cancers including HB 
(Finegold, 2002; Fuertes et al., 2003). The antitumoral activity of CP is in part due to its 
ability to form DNA adducts, mainly with the N7 of guanine and adenosine, which leads 
to the appearance of both intra- and interstrand crosslinks (Eastman, 1990). As a 
consequence, the platinum-DNA adducts in both the nuclear and mitochondrial compart-
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ment inhibit transcription-dependent cell functions that finally lead to apoptosis (Eastman, 
1990; Fuertes et al., 2003). 
 To test whether HGF/SF has an inhibitory effect on CP-induced apoptosis, HB and 
HCC cells were pre-incubated in the presence or absence of 10 and 20 ng/ml HGF/SF 
for 24 h. Directly afterwards, various amounts of CP were added for additional 24 h be-
fore cells were lysed and subjected to the caspase 3-like activity assay (Figure 20). The 
results obtained from these experiments showed that apoptosis induction by CP is con-
centration-dependent. The caspase 3-like activity increased with the amount of CP 
added to the cells. Indeed, the cells that were pre-incubated with HGF/SF showed a re-
duced caspase 3-like activity, suggesting an anti-apoptotic effect of HGF/SF (Figure 20). 
HepG2 cells showed the strongest reduction in caspase 3-like activity after pre-incu-
bation with HGF/SF.  
The stronger effect of HGF/SF on HepG2 cell might be explained by the previously 
observed higher c-Met expression in those cells. Accordingly, in HuH6 cells, where the 
expression of c-Met protein was the lowest, the apoptosis reduction was also lower as 
compared to HepT1 and HepG2 cells. 
 
4.3.2 Camptothecin 
Camptothecin (CPT) and its derivatives (e.g. topotecan) are also frequently used for 
chemotherapeutic treatment of cancer. They are known to specifically target toposo-
merase I by binding non-covalently to DNA strand nicks in a so-called ‘cleavable com-
plex’, stabilizing them and interfering with DNA religation (Fan et al., 1998b). As a result, 
single- and double-strand DNA breaks occur when encountered by a replication fork, 
leading to inhibition of transcription (Bendixen et al., 1990). Cells can repair DNA breaks 
caused by low concentrations of CPT, whereas higher concentrations lead to cell death 
(Darzynkiewicz et al., 1996). 
 It was reasoned whether HGF/SF also exerts an anti-apoptotic effect on CPT-treated 
HB and HCC cells. Like in the previous experiments, the cells were pre-incubated for 
24 h with various HGF/SF concentrations. After this time period, apoptosis was induced 
by various amounts of CPT for 24 h (Figure 21). As expected, CPT is a potent inducer of 
apoptosis in HB and HCC cells. Similar to the effects seen with CP treatment in the 
presence or absence of HGF/SF, CPT-induced caspase 3-like activity could be reduced 
by pre-treatment of the cells with HGF/SF. Notably, although the inducible caspase 3-like 
activity was lower in HepG2 than that of HB cells, pre-treatment with HGF/SF resulted in  
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Figure 20: Apoptosis induction with Cisplatin in HGF/SF-treated cells. 
HB and HCC cells were pre-incubated with indicated amounts of HGF/SF for 24 h and then 
apoptosis was induced by various amounts of CP for additional 24 h. Caspase 3-like activity 
was measured by the fluorogenic DEVD-afc cleavage assay. Values given represent means of 
triplicate measurement. *P<0.005, unpaired t-test. 
* 
* *  * 
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Figure 21: Apoptosis induction with Camptothecin in HGF/SF-treated cells. 
HB and HCC cells were pre-incubated with indicated HGF/SF concentrations for 24 h before 
apoptosis was induced by various amounts of CPT for 24 h. Caspase 3-like activity was 
measured by the fluorogenic DEVD-afc cleavage assay. Values given represent means of 
triplicate measurement. *P<0.03, **P<0.001, unpaired t-test. 
* 
* * ** ** ** 
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the strongest reduction of caspase 3-like activity in these cells, suggesting a higher 
resistance to CPT and higher sensitivity to HGF/SF. 
 
4.3.3 Staurosporine 
Cell permeable stauro-
sporine (STS), isolated 
from Streptomyces stauro-
sporeus, is one of the most 
potent and widely used in-
ducers of apoptosis, which 
is achieved by inhibition of 
PKC and other protein kina-
ses including PKA, PKG, 
S6K, and Src (Tamaoki et 
al., 1986). 
For assay optimization, 
several STS concentrations 
were tested. The optimal 
concentration to induce 
apoptosis in HB and HCC 
cells was found to be 
0.5 µg/ml (data not shown). 
Next, the time-dependent 
activation of apoptosis by 
STS was assessed and the 
ideal time-point for apop-
tosis detection was found 
to be 5 h after stimulation 
(data not shown). To test 
the hypothesis whether HGF/SF is capable of preventing STS-induced apoptosis, HB 
and HCC cells were pre-incubated with various amounts of HGF/SF for 24 h before STS 
stimulation (Figure 22).  
Repeated analysis of caspase 3-like activity revealed that pre-incubation of HB and 
HCC cells with various amounts of HGF/SF could not prevent STS-induced apoptosis, 
Figure 22: Apoptosis induction with staurosporin in 
HGF/SF-treated cells HB and HCC cells were pre-treated with 
indicated HGF/SF concentrations for 24 h and then apoptosis 
was triggered with 0.5 µg/ml staurosporine. Caspase 3-like 
activity was measured by the fluorogenic DEVD-afc cleavage 
assay. Values given represent means of triplicate 
measurement. 
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suggesting that the inhibition of several protein kinases by STS might be too severe and 
causes cell death regardless of any survival signals.  
 
4.3.4 Starvation 
From the previous 
experiments it became 
evident that HGF/SF in-
fluences cell survival. 
Supply of oxygen and 
nutrients is a prerequ-
isite for tumor survival.  
To check whether 
HGF/SF can modulate 
the survival of starving 
cells, HB and HCC cells 
were incubated with 
starvation medium in 
the presence or 
absence of various 
HGF/SF concentrations 
(Figure 23). The star-
vation conditions used 
were not such a strong 
apoptosis stimulus as 
the tested apoptosis in-
ducers. The apoptosis 
rate detected after 24 h 
was increased for un-
treated cells. When 
cells were incubated 
together with HGF/SF, a reduction of caspase 3-like activity could be observed. No 
significant differences between treated and untreated cells were detected at the 15 h 
time point. Of note, the HepT1 cell line was still able to proliferate under reduced serum 
conditions (data not shown). 
Figure 23: Apoptosis induction by starvation in HGF/SF-treated 
cells. HB and HCC cell lines were starved for the indicated time in 
the presence or absence of various HGF/SF concentrations. 
Caspase 3-like activity was measured by the fluorogenic DEVD-afc 
cleavage assay. Values given represent means of triplicate 
measurement. *P<0.03 vs. control; unpaired t-test. 
* 
* 
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4.3.5 Pathways involved in HGF/SF-mediated anti-apoptosis signaling 
To better understand the molecular mechanisms underlying the anti-apoptotic effects 
exerted by HGF/SF, a detailed analysis of the involved pathways was performed. 
Signaling cascade-specific inhibitors were employed to unravel the responsible pathway 
for the observed phenotype. Wortmannin (Wn) was used for inhibition of the PI3K 
pathway (Walker et al., 2000). For a potent inhibition of the MAPK kinase (MEK), 
PD98059 (2’-amino-3’-methoxyflavone) was employed (Alessi et al., 1995). 
In both CP- and CPT-induced HB and HCC cells, co-incubation with HGF/SF 
decreased caspase 3-like activity as previously observed (Figure 24 and Figure 25). 
When cells were pre-treated with Wn together with HGF/SF, apoptosis induction by CP 
resulted again in high caspase 3-like activity, suggesting an important role of PI3K. 
When cells were pre-treated with PD98059 together with HGF/SF, the caspase 3-like 
activity remained at the same reduced level as with HGF/SF pre-treatment alone (data 
not shown). The inhibitors by themselves had no or only minor effects on caspase 3-like 
activity in either induced and non-induced conditions. These experiments show that 
apoptosis inhibition via PI3K/Akt and not the MAPK/ERK-1/2 pathway may be a critical 
component of c-Met oncogenic pathway. 
 
In conclusion, HGF/SF does not stimulate growth of HB and HCC cells, but increases 
their survival and resistance to apoptosis. Thus, in cultured HB and HCC cells, HGF/SF 
could be regarded as a survival factor rather than a growth factor. By serving as a 
survival factor, HGF/SF facilitates the cells to evade from apoptosis and decrease their 
sensitivity to chemotherapy. These results could have a strong impact for the clinical 
setting and might explain the poor prognosis of cancer patients with elevated HGF/SF 
serum levels. 
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Figure 24: Apoptosis induction by Cisplatin (CP) in PI3K-inhibited/HGF/SF-stimulated HB 
and HCC cells. Cells were pre-incubated in the presence or absence of HGF/SF and PI3K 
inhibitor Wn for 24 h. Apoptosis was subsequently induced by 25 µM CP. Caspase 3-like 
activity was measured by the fluorogenic DEVD-afc cleavage assay. Values given represent 
the means of triplicate measurements. *P<0.03, **P<0.003 vs. control; unpaired t-test. 
* 
** 
* 
* 
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Figure 25: Apoptosis induction by Camptothecin (CPT) in PI3K-inhibited/HGF/SF-
stimulated HB and HCC cells. Cells were pre-incubated in the presence or absence of 
HGF/SF and PI3K inhibitor Wn for 24 h. Apoptosis was subsequently induced by 25 nM CPT 
and caspase 3-like activity was measured by the fluorogenic DEVD-afc cleavage assay. Values 
given represent the means of triplicate measurements. *P<0.03; unpaired t-test. 
* 
* * 
* 
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4.4 HGF/SF as scatter factor for HB and HCC cells 
HGF/SF was originally discovered not only as a liver cell mitogenic factor, but also 
as a motogenic factor (Stoker et al., 1987; Weidner et al., 1990). To date, several 
studies have shown the effect of HGF/SF on cell motility and invasion. 
 To investigate the role of HGF/SF on HB and HCC cell scattering, cells were plated 
on collagen I-coated tissue plates and incubated with 10 ng/ml HGF/SF for up to 
72 hours. In addition, to find out which pathway might be involved, HB and HCC cells 
were also incubated with 10 ng/ml HGF/SF in the presence of Wn and PD98059 
(Figure 26 - Figure 28). 
control HGF/SF 
 
HGF/SF 
 + PD98059 
 
 
HGF/SF 
+ Wn 
 
 
HuH6 
Figure 26: Pathway-dependent induction of HuH6 cell scattering by HGF/SF. Cells were 
plated on collagen I in the presence or absence of 10 ng/ml HGF/SF and pathway specific 
inhibitors. Microphotographs were taken after 72 h. 
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 Indeed, HGF/SF induced scattering in all cell lines tested. The most dramatic 
changes in the cell morphology, however, were seen in HepG2 cells (Figure 28). These 
cells completely changed to a spindle-like, fibroblastic cell shape. Also the HB cell lines 
showed the distinct neurite outgrowth and filapodia formation. However, these 
alterations were stronger in HepT1 cells than in HuH6 cells. 
 Notably, co-incubation with the MEK inhibitor PD98059 almost completely blocked 
the scattering phenotype, whereas Wn had no such effect on HGF/SF-stimulated cells, 
suggesting a strong involvement of the MAPK pathway in HGF/SF-induced cell 
scattering and motility. 
 
control HGF/SF 
 
HGF/SF  
+ PD98059 
 
HGF/SF 
+ Wn 
HepT1 
Figure 27: Pathway-dependent induction of HepT1 cell scattering by HGF/SF. Cells 
were plated on collagen I in the presence or absence of 10 ng/ml HGF/SF and pathway 
specific inhibitors. Microphotographs were taken after 72 h. 
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4.4.1 Involvement of HGF/SF in cell-cell adhesion regulation 
During cell scattering the cell-matrix and cell-cell adhesion capacity of the cells 
are dramatically altered. To achieve an increase in cell motility, cells have to weaken 
or even completely loose their cell-cell contacts. In epithelial layers, adherens and 
tight junctions and desmosomes link cells to each other (Tsukita et al., 2001). Loss 
of cell-cell adhesion followed by the dissociation of epithelial structures is a 
prerequisite for increased cell motility, but also for tumor invasion (Hanahan and 
Weinberg, 2000).  
It was therefore analyzed whether HGF/SF-induced cell scattering is directly 
accompanied with downregulation of adherens and tight junctions. 
control  HGF/SF 
 
HGF/SF 
+ Wn 
PD98059  
 + 10 ng/ml 
HGF/SF 
 
HepG2 
HGF/SF
PD98059 
 
Figure 28: Pathway-dependent induction of HepG2 cell scattering by HGF/SF. Cells 
were plated on collagen I in the presence or absence of 10 ng/ml HGF/SF and pathway 
specific inhibitors. Microphotographs were taken after 72 h.. 
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Next it was checked by quantitative real-time RT-PCR (qRT-PCR), whether HGF/SF 
stimulation causes a change in the mRNA levels of the adherens junction protein 
E-cadherin and tight junction protein claudin-3 (Figure 29). It was observed that 
downregulation of junction proteins mRNA takes place at an early time point after 
HGF/SF stimulation. The first significant decrease could be detected as early as 3 h 
after the start of HGF/SF incubation. After 8 h, the mRNA levels were reduced by 80% 
for claudin-3 and by 60% for E-cadherin. These results indicate a strong influence of 
HGF/SF in regulating adherens and tight junctions. 
 
4.4.2 Repressors of adherens and tight junctions 
It has been reported that several transcriptional repressors are responsible for the 
downregulation of adherens and tight junctions, namely Snail, Slug, Twist, Smad-
interacting protein (SIP)-1, E12/E47 (Grunert et al., 2003; Huber et al., 2005; Nieto, 
2002; Savagner, 2001). By binding to specific DNA sequences in the promoter, termed 
E-boxes, these repressors prevent transcription, leading to the disruption of adherens 
and tight junctions. Cell-cell adhesion is frequently lost during malignant tumor 
progression by gene mutation, transcriptional repression or protein degradation 
(Cavallaro and Christofori, 2004; Gumbiner, 2000), therefore a pivotal role of any of 
these repressors in HGF/SF-mediated tight and adherens junctions loss was hypo-
Figure 29: Kinetics of HGF/SF-mediated downregulation of E-cadherin and 
claudin-3 mRNA. HepG2 cells were incubated with 10 ng/ml HGF/SF in the 
presence of MG132 and LiCl. At indicated time points mRNA was analyzed by qRT-
PCR. Values represent means of triplicate measurements ± standard deviations in 
comparison to untreated control samples. 
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thesized. To investigate whether these factors were also involved in HGF/SF-induced 
cell scattering and loss of cell-cell contacts, expression levels of Snail, Slug, and Twist 
were checked in HepG2 cells by qRT-PCR. 
Preliminary experiments suggested that Snail mRNA was expressed in HepG2 cells 
and induced after 8 h HGF/SF stimulation. In contrast, Slug mRNA levels were low and 
not increased after HGF/SF stimulation. Similarly, Twist mRNA levels were rather low 
and insignificantly increased after HGF/SF treatment (data not shown), implicating a 
dominant role for Snail in HGF/SF-induced cell scattering. Therefore, further 
experiments were performed to characterize in more detail the role of Snail in HGF/SF-
mediated cell motility. 
Snail is an extremely labile protein with a half-life of only 25 minutes and difficult to 
detect by conventional immunoblotting methods. Thus, the GSK-3β inhibitor lithium 
chloride (LiCl) and the proteasome inhibitor MG132 were added to the culture medium 
to prevent the rapid degradation of Snail protein by the proteasomal pathway (Zhou et 
al., 2004). In the absence of these inhibitors, Snail protein was barely detectable in 
HepG2 cells (Figure 30A), whereas treatment with MG132 or LiCl or both combined led 
to a slight stabilization of the protein. Notably, when HGF/SF was added to inhibitor-
treated cells, Snail protein levels were markedly elevated. In contrast, treatment of cells 
with HGF/SF in the absence of inhibitors did not result in increased Snail protein levels. 
These experiments indicate that HGF/SF is able to induce the expression of Snail in 
HepG2 cells, but that increased Snail protein levels are only detectable by preventing 
proteasomal degradation. 
A comparison of the Snail protein levels in HepG2 cells to the HB cells revealed also 
Snail protein induction in HuH6 and HepT1 cells, yet the strongest induction could be 
detected in HepG2 cells (Figure 30B). Interestingly, HepG2 cells showed the strongest 
scattering phenotype after HGF/SF treatment, suggesting a possible link between Snail 
expression levels and the degree of scattering. This observation could be based on the 
higher c-Met levels and c-Met and MAPK phosphorylation detected earlier in this study. 
For this reason, the following experiments were performed with HepG2 cells and not 
with HuH6 and HepT1 cells. 
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Next, I determined whether HGF/SF directly affected Snail gene expression. For this, 
HepG2 cells were treated with HGF/SF in the presence or absence of LiCl and MG132 
for 8 h. qRT-PCR analysis revealed that Snail mRNA levels were approximately 8-fold 
(±3.1) upregulated in HepG2 cells treated with HGF/SF (Figure 31). Interestingly, when 
HepG2 cells were pre-incubated with proteasome and GSK-3β inhibitors, Snail mRNA 
levels increased up to 40-fold (±1.4) and co-incubation with inhibitors and HGF/SF 
elevated Snail mRNA levels up to 50-fold (±1.8). These results suggest that a 
Figure 30: Immunoblotting of Snail in HB and HCC cells. 
(A) HepG2 cells were incubated with 10 ng/ml HGF/SF for 8 h in the presence or absence of 
GSK-3β inhibitor LiCl (40 mM) and proteasome inhibitor MG132 (10 µM). Cell lysates were sub-
jected to immunoblotting using an anti-Snail antibody. Equal loading of proteins was confirmed 
by Ponceau S staining. 
(B) HuH6, HepT1 and HepG2 cells were incubated with 10 ng/ml HGF in the presence or ab-
sence of the indicated inhibitors. Immunoblot analysis with antibodies against Snail and β-actin 
reveal that HGF/SF-induced levels of Snail protein correlate with the degree of scattering. 
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Figure 32: A Snail-promoter luciferase-
reporter construct was transiently trans-
fected into HEK293 cells. Cells were 
incubated with HGF/SF for 24 h, before 
luciferase activities were determined. 
Relative light units (RLU) represent firefly 
luciferase (LAR) normalized against 
Renilla luciferase activity (RAR). Values 
given represent means and standard 
deviations of triplicate measurements. 
*P=0.0031; unpaired t-test. 
proteolytically sensitive protein, possibly Snail itself, cooperated with HGF/SF to induce 
Snail gene transcription and/or to stabilize its mRNA. 
Similar experiments in MDCK cells revealed comparable results: HGF/SF by itself 
moderately increased Snail mRNA expression 
(2.2-fold ±0.8; data not shown). HGF/SF also 
significantly increased Snail mRNA levels in the 
presence of LiCl and MG132. Taken together, 
HGF/SF treatment of epithelial cells induced 
Snail expression not only at the protein level but 
also at the mRNA level. 
 
4.4.3 Snail is a direct target of HGF/c-Met 
signaling 
I then assessed whether the observed Snail 
upregulation is due to a directly activation of the 
Snail promoter. To address this question, 
human embryonal kidney (HEK) 293 cells were 
transiently transfected with a reporter construct 
in which the mouse Snail promoter sequence 
was cloned upstream of the firefly luciferase 
gene (Peinado et al., 2003). Upon HGF/SF 
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Figure 31: Snail mRNA 
levels in HepG2 cells. 
HepG2 cells were incu-
bated with HGF/SF for 8 h 
in the presence or absence 
of MG132 or LiCl. Snail 
mRNA levels were ana-
lyzed by qRT-PCR. Values 
given are means and stan-
dard deviations of triplicate 
measurements. *P=0.0358, 
**P=0.0007, ***P<0.0001, 
unpaired t-test. 
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Figure 33: Analysis of different shSnail and control shRNA expressing HepG2 clones. 
shSnail-expressing (S-1, S-2, and S-3) and control shRNA-expressing (C-1, C-2) HepG2 clones 
were incubated with MG132 and LiCl for 4 h. mRNA expression was analyzed by qRT-PCR 
with specific primers against the coding region and the 3’-untranslated region (3’UTR) of Snail, 
respectively. Values are the averages and standard deviations of triplicate measurements. 
*P<0.03, **P<0.01; unpaired t-test. 
treatment, Snail promoter activity was elevated by 1.8-fold (±0.09) (Figure 32). These 
results indicate that HGF/SF signaling directly induces the Snail promoter. The rather 
moderate induction is in agreement with previous reports using the same promoter-
reporter construct (Peinado et al., 2003) and is consistent with the levels of Snail mRNA 
upregulation detected in HepG2 and MDCK cells.  
 
4.4.4 Generation of shSnail clones 
Previous results indicated that Snail plays an important role in HGF/SF-induced cell 
scattering. To assess whether Snail upregulation was required for HGF/SF-induced cell 
scattering, stably transfected HepG2 cell lines expressing small hairpin RNA against 
Snail (shSnail) to ablate Snail expression were generated. 
Various independent shSnail-expressing clones (clones S-1, S-2, S-3) and control 
shRNA clones (C-1, C-2) were analyzed for Snail mRNA and protein expression. Two 
different sets of primers were included in this experiment, one primer pair comple-
mentary to Snail and one pair complementary to the 3’-untranslated region (3’UTR) of 
Snail mRNA. Clones expressing shSnail (S-1, S-3) showed up to 80% repression of 
Snail mRNA and levels, whereas control clones did not exhibit any significant reduction 
in Snail mRNA (Figure 33). Immunoblotting analysis revealed a decrease in Snail 
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protein levels in the shSnail expressing HepG2 cells in comparison to control 
transfected HepG2 cells (Figure 34).  
More important, however, was the question whether HepG2 cells with repressed 
Snail expression were still able to scatter after the stimulation with HGF/SF. Hence, the 
degree of scattering of shSnail-expressing clones S-1 and S-3 and control vector-
transfected cells was observed over a time period of 72 h after the onset of HGF/SF 
treatment. Control shRNA clones showed normal scattering behavior as observed with 
untransfected HepG2 cells (Figure 35A - B). In contrast, shSnail-expressing clones S-1 
and S-3 exhibited a discernible reduction in HGF/SF-induced cell scattering, indicating 
that Snail function is required for this process (Figure 35C - F). Interestingly, the Snail 
mRNA and protein levels correlate with the scattering behavior of shSnail-expressing 
HepG2 cells, indicating that the presence of Snail is essential for HGF/SF-induced cell 
scattering and increased cell motility. Notably, forced expression of Snail by itself was 
not sufficient to induce a scattering phenotype in the absence of HGF/SF, as for 
example tested in HEK293 cells expressing a stabilized form of Snail (Snail-8SA) and in 
HepG2 cells transiently transfected with Snail-8SA (data not shown). In conclusion, 
while Snail appears to be required for HGF/SF-induced cell scattering, it is not sufficient 
to replace HGF/SF’s activity.  
Figure 34: HepG2 clones expressing shSnail (S-1, S-2, S-3) or a 
control (C-1, C-2) shRNA were incubated with LiCl, MG132, and 
10 ng/ml HGF/SF for 8 h. Snail and β-actin protein levels were 
analyzed by immunoblotting. 
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4.4.5 Pathways involved in HGF/SF-induced Snail upregulation 
Next, I investigated whether the regulation of Snail expression and Snail stabilization 
could depend on the activity of specific signaling cascades. 
4.4.5.1 GSK-3β 
The Snail protein exhibits two consensus sites for GSK-3β serine phosphorylation, 
leading to its nuclear export and degradation by the proteasome (Zhou et al., 2004). In 
Figure 35: shSnail prevents HGF/SF-induced cell scattering. 
shSnail-expressing (S-1, S-3) and control shRNA-expressing (C-2) 
HepG2 clones were incubated with or without 10 ng/ml HGF/SF. Cell 
scattering was observed by light microscopy after 72 h of HGF/SF 
treatment (Magnification: 200x). 
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addition, GSK-3β has been shown to directly inhibit Snail transcription (Bachelder et al., 
2005). It has been previously reported that GSK-3β activity could be inhibited by 
HGF/SF signaling (Papkoff and Aikawa, 1998), suggesting a possible link between 
HGF/SF signaling and increased Snail levels. Therefore, the involvement of GSK-3β in 
HGF/SF-induced Snail upregulation was analyzed in HepG2 and MDCK cells.  
Immunoblot analysis revealed an increase in phosphorylation of GSK-3β in HepG2 
cells and MDCK cells after treatment with LiCl compared to untreated cells (Figure 36). 
However, HGF/SF treatment did not lead to further GSK-3β phosphorylation, suggesting 
that GSK-3β activity was not involved in HGF/SF-mediated Snail expression. 
To evaluate whether HGF/SF-mediated signaling could stabilize Snail protein 
independent of GSK-3β activity, HEK293 cells were transiently transfected with a Flag-
tagged Snail-8SA that cannot be phosphorylated by GSK-3β (Zhou et al., 2004). 
Immunoblot analysis of HEK293 lysates with an anti-Flag antibody revealed that 
HGF/SF-treated cells exhibited higher levels of Flag-tagged Snail-8SA, indicating that 
the Snail protein was stabilized upon HGF/SF treatment independently of GSK-3β-
mediated phosphorylation of Snail (Figure 37). Of note, the Flag-tagged Snail-8SA was  
Figure 36: Immunoblotting 
of GSK-3β phosphory-
lation. 
HepG2 and MDCK cells 
were pre-incubated with 
LiCl and MG132 for 30 min 
and then stimulated with 10 
ng/ml HGF/SF for further 
30 min. Whole cell lysates 
were analyzed by immuno-
blotting with specific anti-
bodies against phospho-
rylated (p)-GSK-3β and 
total (t)-GSK-3β. 
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under the control of the CMV promoter, which is not regulated by HGF/SF signaling, 
suggesting that other post-translational effects induced by HGF/SF lead to Snail 
stabilization. 
 
4.4.5.2 PI3K and MAPK 
As described above, specific inhibition of the MAPK pathway but not the PI3K 
pathway resulted in a repression of HGF/SF-induced cell motility (Figure 26 - Figure 28). 
To identify if this pathway-specific effect could also be seen with HGF/SF-induced 
Snail upregulation, HepG2 cells were stimulated with HGF/SF in the presence or 
absence of the specific pathway inhibitors Wn and PD98059 (Figure 38). In the 
presence of the MAPK pathway inhibitor PD98059 the HGF/SF-induced Snail 
expression was prevented, while the PI3K inhibitor Wn had no effect on HGF/SF-
induced Snail mRNA expression in HepG2 cells. These results further indicate that the 
MAPK pathway plays a critical role in HGF/SF-induced Snail expression, whereas the 
PI3K does not seem to be involved. The inhibitors themselves had no (PD98059) or only 
a minor (Wn) effect on Snail mRNA expression. Interestingly, Snail expression levels 
detected by qRT-PCR correlate with the scattering phenotype as observed earlier in this 
study (Figure 26 -Figure 28). 
Taken together, these results demonstrate that HGF/SF induces cell scattering and 
increased motility by utilizing the MAPK signal transduction pathway, whereas the GSK-
3β and PI3K pathways are not involved. 
 
 
 
Figure 37: HGF/SF-mediated Snail 
stabilization. 
HEK293 cells were transiently transfected 
with a plasmid encoding Flag-tagged 
Snail-8SA, and 24 h later stimulated with 
10 ng/ml HGF/SF. After an additional 24 h, 
cells were analyzed by immunoblotting 
with anti-Flag-tag antibodies. Immuno-
blotting for β-actin was used as loading 
control. 
HGF/SF 
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4.4.6 HGF/SF activates Egr-1 to induce Snail expression 
To further elucidate the molecular mechanisms by which HGF/SF-stimulated MAPK 
signaling induced Snail expression, I investigated the potential involvement of candidate 
transcription factors. Several recent studies have shown that HGF/SF upregulates 
PDGF and VEGF (Worden et al., 2005), CD44v6 (Recio and Merlino, 2003), angiotensin 
converting enzyme (ACE) (Day et al., 2004), and fibronectin (Gaggioli et al., 2005) in a 
MAPK-dependent and PI3K-independent manner through the early growth response 
factor (Egr)-1. 
Thus, an in silico analysis of the Snail promoter sequence using the MatInspector 
software was applied (Cartharius et al., 2005). The survey identified four putative Egr-1 
binding sites between -450 bp and –50 bp upstream of the Snail gene transcriptional 
start site (Figure 39A). To assess whether Egr-1 was expressed in HepG2 cells and 
whether its expression was affected by HGF/SF, qRT-PCR analyses were performed. 
These revealed a twelve-fold (±4.7) transient increase in Egr-1 mRNA levels by 
HGF/SF, with maximum levels after 1 h and a decline to basal levels within 3 h of 
HGF/SF stimulation (Figure 39B). Immunoblotting analysis showed slightly delayed 
kinetics of the upregulation of Egr-1 protein levels, which peaked after 2 to 3 h and 
declined afterwards (Figure 39C). 
Snail mRNA levels steadily increased beginning at 2 h, after the first appearance of 
Egr-1 protein (Figure 39B), and increased Snail protein levels could be detected after 
Figure 38: The MAPK pathway mediates Snail induction. HepG2 cells were 
treated with 10 ng/ml HGF/SF for 8 h in the presence or absence of pathway 
specific inhibitors Wn (1 µM) and PD98059 (20 µM), respectively. Snail mRNA 
levels were determined by qRT-PCR. *P<0.0001; unpaired t-test. 
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5 h, again only in the presence of proteasome inhibitors (Figure 39C). The early 
increase in Snail expression already correlated with the downregulation of Snail target 
genes, such as E-cadherin or claudin-3 during HGF/SF treatment, with an initial decline 
in mRNA levels after 3 h and a further reduction during 8 h of HGF/SF incubation time 
(Figure 29).  
These results suggest the following order of events in HGF/SF-induced Snail 
expression: (i) HGF/SF-mediated MAPK activation induces the expression of Egr-1, 
which in turn (ii) activates Snail gene expression and (iii) the subsequent repression of 
E-cadherin and claudin-3 gene expression, finally (iv) leading to cell scattering. 
 
4.4.7 The Snail gene is a target of Egr-1 
To validate a direct involvement of Egr-1 in Snail expression, the appropriate 
experiment would be to overexpress Egr-1 by transfection using a plasmid encoding for 
the wildtype Egr-1. Unfortunately, it has been previously reported that Egr-1 induces the 
expression of its co-repressor Nab2, thereby establishing a negative feedback loop and 
preventing a direct analysis of wildtype Egr-1 overexpression (Kumbrink et al., 2005). To 
circumvent this problem, HEK293 cells were transfected with a plasmid encoding the 
Egr-1 DNA binding domain fused to the CREB-2 activation domain (nabR-Egr-1), a 
construct that is resistant to Nab2’s repressive activity (Al-Sarraj et al., 2005). Luciferase 
reporter assays revealed a concentration-dependent activation of the Snail promoter by 
nabR-Egr-1, indicating that Egr-1 is sufficient for activating Snail gene expression 
(Figure 40). Next, HepG2 cells were transfected with a plasmid encoding for a 
dominant-negative (dn) Egr-1 (Al-Sarraj et al., 2005), and HGF/SF-induced Snail ex-
pression was monitored by qRT-PCR (Figure 41). In these experiments, the presence of 
dnEgr-1 completely abolished HGF/SF-induced Snail expression, further indicating that 
Egr-1 is indeed required for HGF/SF-mediated Snail expression. In summary, these 
results propose an Egr-1-controlled regulation of the Snail promoter. 
Also, to determine whether Egr-1 could directly bind to the Snail promoter chromatin 
immunoprecipitation (ChIP) experiments were performed with anti-Egr-1 antibodies 
followed by PCR analysis with primers specific for the Snail promoter. Egr-1 specifically 
bound to the Snail promoter 1 h after HGF/SF stimulation, while no binding occurred in 
the absence of HGF/SF (Figure 42A). 
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Figure 39: Snail regulation by Egr-1. 
(A) Putative Egr-1 binding sites within 650 bp upstream of the transcriptional start site of the Snail 
gene (indicated by an arrow) are highlighted by boxes. 
(B) HepG2 cells were incubated with HGF/SF, MG132, and LiCl, and Egr-1 and Snail mRNA 
levels were analyzed by qRT-PCR at the time points indicated. Values represent the averages 
and standard deviations of triplicate measurements. 
(C) HepG2 cells were incubated with HGF/SF in the presence of MG132 and LiCl. 
Immunoblotting was performed with specific antibodies against Egr-1, Snail, and β-actin at the 
time points indicated. 
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 Quantitative PCR analysis of anti-Egr-1-precipitated chromatin with primers specific 
for an Egr-1 binding site within the Snail promoter confirmed this observation (Figure 
42B). Altogether, these results indicate that the Snail promoter is a direct target of the 
Egr-1 transcription factor upon HGF/SF stimulation. 
Figure 40: Egr-1 activates the Snail promoter. 
HEK293 cells were transiently transfected with a plasmid encoding a constitutive-active Egr-1 
construct, in which the Egr-1 DNA binding domain was fused to the CREB-2 activation domain, or 
a dominant-negative mutant (dnEgr-1). Snail-promoter luciferase-reporter and Renilla luciferase 
constructs were co-transfected with the Egr-1 plasmids. Cells were incubated with HGF/SF for 
24 h, before luciferase activities were determined. Relative light units (RLU) represent firefly 
luciferase (LAR) normalized against Renilla luciferase activity (RAR). Values are means of 
induction ± standard deviations of triplicate measurements in comparison to untreated control 
samples. *P=0.0145, **P<0.001; unpaired t-test. 
Figure 41: Snail expres-
sion critically depends on 
Egr-1 function. 
HepG2 cells were tran-
siently co-transfected with a 
dominant-negative version 
of Egr-1 (dnEgr-1) and trun-
cated CD4. CD4+-express-
ing cells were selected us-
ing MACS beads coated 
with anti-CD4 antibody, 
treated with HGF/SF for 
8 h, before Snail mRNA 
levels were measured by 
qRT-PCR. ***P=0.0018; un-
paired t-test. 
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Figure 42: Egr-1 directly binds to the Snail promoter. 
(A) Chromatin immunoprecipitation (ChIP) analysis of Egr-1 binding to the Snail 
promoter. HEK293 cells were stimulated with HGF/SF for 1 h before being 
subjected to ChIP analysis. Anti-Egr-1 antibodies or IgG were used to 
immunoprecipitate DNA-containing complexes. Subsequent PCR was 
performed with primers complementary to the Snail promoter region containing 
the Egr-1 binding sites. DNA samples were analyzed by agarose gel 
electrophoresis. 
(B) Quantitative real time PCR analysis of the Snail promoter region immuno-
precipitated with antibodies against Egr-1, as described in (A). Results indicate 
amplified Snail promoter levels normalized against PCR reactions detecting an 
unrelated promoter. Bar graphs represent the means and standard deviations. 
*P=0.0432; unpaired t-test. 
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4.4.8 Transient upregulation of Snail 
To analyze the long-term kinetics of HGF/SF-mediated gain of Snail expression, and 
loss of adherens and tight junction functions, HepG2 cells were treated with HGF/SF for 
10 days. To avoid cell death by prolonged exposure to the proteasome inhibitor MG132 
and the GSK-3β inhibitor LiCl, these were added 8 h prior to cell lysis for each time 
point. Analysis of Snail mRNA expression revealed that HGF/SF-induced Snail 
expression reached its maximum 8 h after HGF/SF stimulation and declined with longer 
treatment (Figure 43A). Immunoblot analysis showed that HGF/SF-induced Snail protein 
expression follows a similar kinetic (Figure 43B). As expected, with increased Snail 
Figure 43: HGF/SF induces transient upregulation of Snail. 
(A) HepG2 cells were treated with HGF/SF in the absence of MG132 and LiCl. Snail 
mRNA expression levels were determined by qRT-PCR at the time points indicated. 
Bar graphs represent the means and standard deviations of triplicate measurements. 
*P=0.0023, **P=0.0013, ***P<0.0001; unpaired t-test. 
(B) HepG2 cells were incubated with HGF/SF for the time periods indicated. LiCl and 
MG132 were added 8 h before lysis of the cells. Snail protein levels and β-actin as 
loading control were analyzed by immunoblotting. 
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expression, E-cadherin (Figure 44A) and claudin-3 (data not shown) mRNA levels 
declined, yet remained low at time points where Snail expression had already returned 
to basal levels. Conversely, immunoblot analysis of whole cell lysates revealed that total 
E-cadherin protein levels remained unchanged after this time period (Figure 44B), 
suggesting a different regulation of the protein level or protein subcellular localization. 
 
 
Figure 44: HGF/SF induces downregulation of E-cadherin mRNA, but not protein. 
(A) HepG2 cells were incubated with HGF/SF for the time points indicated, and E-cadherin 
mRNA levels were analyzed by qRT-PCR. Values represent the means and standard 
deviations of triplicate measurements. 
(B) HepG2 cells were incubated with HGF/SF for the time periods indicated. E-cadherin 
protein levels and vinculin as loading control were analyzed by immunoblotting. 
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4.4.9 Signals for downregulating Snail 
The observed kinetics in Snail and Egr-1 expression suggest a feedback loop 
mechanism, where Snail would repress its own activator. Recently, it has been reported 
that Snail is able to repress its own expression (Peiro et al., 2006). Inspection of the 
Egr-1 promoter sequence also revealed the existence of five E-boxes, which could be 
potential binding sites for Snail (Figure 45A). To test whether overexpression of Snail 
inhibited HGF/SF-induced Egr-1 activation, HEK293 cells expressing Snail under the 
control of the tetracycline-inducible system were generated (HEK293-FlpInTRex-Snail-
8SA). These cells were cultured with and without doxycycline before stimulation with 
HGF/SF and analysis of Egr-1 mRNA expression by qRT-PCR.  
In the presence of high levels of induced Snail, the amounts of Egr-1 mRNA declined 
in the presence and even in the absence of HGF/SF (Figure 45B). Moreover, ChIP 
experiments in HepG2 cells with anti-Snail antibodies followed by PCR with primers 
complementary to the Egr-1 promoter region containing the E-boxes revealed specific 
Snail binding to the Egr-1 promoter (Figure 45C). These results suggest that Snail 
directly represses Egr-1 expression, thus exerting a negative feedback regulation on its 
own activator and on its own promoter (Peiro et al., 2006). 
 
 
Figure 45: Negative feedback loop: Snail represses its own activation. 
(A) Schematic representation of the promoter regions of the Snail target genes E-cadherin, 
claudin-3, Snail, and Egr-1. Open boxes = E-box; +1 = transcription start site; ORF = open 
reading frame. 
(B) HEK293-FlpInTRex-Snail-8SA cells were cultured in the presence or absence of 
doxycycline for 24 h and then incubated with HGF for 1 h before subjected to qRT-PCR 
analysis for Egr-1 mRNA levels. Bar graphs represent means ± standard deviations of 
triplicate measurements. 
(C) ChIP analysis of Snail binding to the Egr-1 promoter. HepG2 cells were incubated with 
HGF for 1 h before proteins were cross-linked to DNA, and chromatin-protein complexes were 
immunoprecipitated with an antibody against Snail. PCR was performed with primers specific 
for the Egr-1 promoter region containing E-box binding sites. DNA samples were analyzed by 
2% agarose gel electrophoresis. 
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5 Discussion 
Hepatoblastoma (HB) is the most common pediatric malignant liver tumor, while 
hepatocellular carcinoma (HCC) is among the top five leading causes for cancer death. 
Elevated levels of HGF/SF can be found in HB and HCC cancer patients with a high 
tumor relapse rate and thus, are often associated with poor prognosis (Ueki et al., 1997; 
von Schweinitz et al., 1998). HGF/SF contributes to many physiological processes 
including organogenesis, wound healing, and tissue remodeling, but also participates 
widely in the metastatic process during tumor progression (Birchmeier et al., 2003; Jiang 
et al., 2005). Activation of the RTK c-Met by HGF/SF results in the recruitment of several 
signal transducers that regulate dissociation of adherens and tight junctions, and the 
stimulation of cellular motility, survival, proliferation, and morphogenesis (Martin et al., 
2004; Thiery, 2002; Weidner et al., 1993). 
Hence, in this study we investigated how HGF/SF contributes to the progression of 
HB and HCC and which underlying molecular mechanisms are involved. In a cell culture 
model of established HB and HCC cell lines, the various cellular responses evoked by 
HGF/SF were analyzed and quantitated. We have found that the highly differentiated 
HCC cell line expresses the highest levels of c-Met receptor when compared to the less 
differentiated HB cell lines. This corresponds to a higher sensitivity to HGF/SF 
stimulation. In consequence, these cells show stronger migratory behavior compared to 
HB cells. Also, as seen by apoptosis induction assays, these cells have a reduced 
sensitivity towards apoptotic stimuli and in the presence of HGF/SF caspase 3-like 
activities are reduced, suggesting a molecular mechanism for the higher malignancy 
observed in HCC. 
 
5.1 HGF/SF as a proliferation factor for HB and HCC 
Increased proliferation of tumor cells has been acknowledged as a key element for 
tumor growth and progression (Hanahan and Weinberg, 2000). HGF/c-Met signaling 
has been associated with higher proliferation rates, depending on the target cell (Jiang 
and Hiscox, 1997; Weidner et al., 1993). We thus assessed whether HGF/SF could 
contribute to increased cell proliferation by [3H]-thymidine incorporation, cell counts and 
MTT assays. In none of these assays an increased growth rate was observed upon 
treatment with HGF/SF. To test the possibility that the serum present in the culture 
medium could mask the effects elicited by HGF/SF stimulation, growth curves with 
Discussion 
86 
reduced serum conditions (2% FCS) were performed. Again, no increased growth rate 
could be detected in HB and HCC cell lines. Interestingly, when cells were grown under 
almost serum-free conditions (0.5% FCS), only the HepT1 cell line was able to 
proliferate, while the HuH6 and HepG2 cell lines underwent apoptosis, which could 
partially be inhibited by HGF/SF pre-incubation (see below). 
It was previously reported that HB carried an activating mutation in β-catenin and 
displayed increased proliferation associated with cytoplasmic and nuclear β-catenin 
staining along with increased staining for c-Myc and cyclin D1 (Ranganathan et al., 
2005; Takayasu et al., 2001). Aberrant Wnt/β-catenin activation has been observed in 
70% of all HB and 20 – 40% of all HCC, which is one of the highest β-catenin mutation 
rates among solid tumors (Polakis, 2000). The HB and HCC cell lines used carry 
mutations in the β-catenin gene. In this respect, the cell lines even resemble the original 
tumors, since they carry the same mutations (Koch et al., 1999). Hence, it might be 
possible that these cell lines already have high c-Myc and cyclin D1 protein levels and 
thus increased proliferation rates, which cannot be further stimulated by HGF/SF 
treatment. Detailed analysis of c-Myc and cyclin D1 mRNA and protein levels could 
provide an adequate answer to this question. 
HGF/SF-stimulated recruitment of STAT3 to the c-Met receptor was previously shown 
as a crucial step in liver regeneration and tubule formation (Boccaccio et al., 1998; 
Borowiak et al., 2004). In addition, constitutive activation of STATs has been determined 
in a wide variety of human cancers. Therefore, this signaling pathway was examined. 
Given the shared common structural features of STAT proteins, such as the SH2-
phosphotyrosine interaction domain and the central DNA-binding site (Becker et al., 
1998), all STAT members were analyzed. 
Treatment of HB and HCC cells with IFN-γ, IL-4, and IL-6 resulted in normal STAT 
activation. However, upon stimulation of the cells with various HGF/SF, EGF or SCF 
concentrations for different time periods, no STAT activation could be detected, 
suggesting that these growth factors have no influence on the Jak/STAT pathway 
activation in these cells. Since no HGF/SF-mediated activation of STAT proteins has 
been shown in HB and HCC cells before, this behavior could be a cell type-specific 
effect. Interestingly, HepT1 was the only cell line that did not respond to IFN-α treatment 
with STAT phosphorylation. Defects in the Jak/STAT pathway of HepT1 may render 
these cells unresponsive to growth-inhibiting cytokines such as IFN-α and may impart a 
growth advantage. This was seen in the proliferation studies, where increased growth of 
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HepT1 cells was observed in comparison to other HB cells, even under serum-free 
conditions. 
Cellular proliferation might be necessary, but not sufficient to obtain a transformed 
cellular phenotype. Due to the pleiotropic nature of HGF/SF and its ability to activate 
several signaling cascades, the maintenance of cell survival and induction of motogenic 
pathways may play an even more important role in HGF/SF’s oncogenic signaling. 
Accordingly, HGF/SF-transfected Chinese hamster ovarian (CHO) cells showed 
increased chemoresistance to chemotherapeutic agents, albeit only a slight increase in 
cell proliferation (Meng et al., 2000). Jiang and Hiscox also reported that an increased 
sensitivity to HGF/SF did not translate into a mitotic response, but instead led to 
increased invasion (Jiang and Hiscox, 1997). 
 
5.2 HGF/SF as an antiapoptotic signal for HB and HCC cells 
Perturbation of the balance between cell survival and apoptosis may lead to either 
excessive cell death or survival and plays a pivotal role in the pathogenesis of a large 
number of diseases, including cancer. Previous studies by others demonstrated that 
HGF/SF is a survival factor with potent ability to promote cell survival by inhibiting 
apoptosis (Fan et al., 1998a; Liu, 1999; Yo et al., 1998). Accordingly, dysregulation of 
c-Met and HGF/SF signaling has emerged as a crucial feature of many human 
malignancies (see Table 2). However, to date little is known about HGF/SF-induced cell 
survival in HB and HCC. 
We found, that one of HGF/SF’s critical roles in HB and HCC tumor progression is 
related to higher cell survival and enhanced resistance against apoptosis-inducers. 
Some of these apoptotic inducers are used for chemotherapy, thereby providing a 
possible rationale for the correlation between elevated HGF/SF serum levels and 
chemotherapy-resistant HB and HCC.  
The underlying mechanisms of the observed effects could be explained by the 
activation of the PI3K/Akt pathway in HB and HCC. Inhibition of PI3K prevented 
HGF/SF-induced cytoprotection against apoptotic stimuli and HGF/SF treatment led to 
phosphorylation of Akt/PKB. PI3K/Akt-mediated serine residue phosphorylation of Bad 
leads to its dissociation from Bcl-xL and binding to 14-3-3, thereby inactivating Bad 
function (Figure 46). Bcl-xL is then free to bind to APAF-1 and block APAF-1’s ability to 
activate the cell death protease caspase 9, which in turn activates the caspase 3 (Datta 
et al., 1999; Kennedy et al., 1999).  
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Changes of caspase 3-like activity 
upon HGF/SF pre-incubation were 
detected in this study. Indeed, as shown 
by others, overexpression of Bad in-
creased apoptotic death in wild-type 
human proximal tubular epithelial (HKC) 
cells but not in HKC cells stably trans-
fected with an expression vector con-
taining human HGF/SF cDNA (H4 cells) 
(Liu, 1999). Immunoblotting confirmed 
that the Bad protein overexpressed in 
H4 cells was fully phosphorylated at the 
Ser136 site and thereby inactive. Interest-
ingly, Wn was also shown to inhibit 
phosphorylation of Akt/PKB and Bad in 
HEK293 cells (Liu, 1999). Thus, the 
finding that HGF/SF inhibits apoptosis in 
a PI3K-dependent fashion is consistent with the notion that the PI3K signaling pathway 
plays an essential role in mediating growth factor-dependent cell survival (Datta et al., 
1999; Franke et al., 1997a) 
A second possible mechanism would be a direct upregulation of the anti-apoptotic 
protein Bcl-xL through Akt/PKB as was previously shown in vitro and in vivo (Dai et al., 
2003; Fan et al., 2000; Liu, 1999). Prolonged HGF/SF pre-incubation blocked apoptosis 
induced by Camptothecin, Adriamycin, X-rays, and ultraviolet radiation (Fan et al., 
1998a; Meng et al., 2000). In this instance, increased Bcl-xL protein levels correlated 
with the degree of protection against apoptosis. Thus, the persistent presence of 
HGF/SF may contribute to the development of a chemoresistant phenotype in HB and 
HCC. However, our approaches to show increasing Bcl-xL protein concentrations in HB 
and HCC failed for technical reasons. Further experiments to address this second 
possible mechanism, would include immunoblotting for the Bcl-xL protein and the 
phosphorylated Ser136 residue of Bad in HB and HCC cells upon HGF/SF treatment. 
Such effects of HGF/SF on Akt/PKB phosphorylation and Bcl-xL protein and mRNA 
levels upregulation were previously observed in vivo after partial hepatectomy (Hong et 
al., 2000).  
Figure 46: Model of HGF/SF-mediated 
phosphorylation and inactivation of Bad. 
HGF/SF activates Akt/PKB, which phospho-
rylates Bad, thus inactivation and cell survival. In 
the absence of survival factors and Akt/PKB 
activity, Bad is dephosphorylated. Dephos-
phorylated Bad interacts with pro-survival Bcl-2 
family members, such as Bcl-xL, and inactivates 
them, causing cell death. Modified from (Datta et 
al., 1999). 
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Transient Bad phosphorylation has a short-term cytoprotective effect, whereas 
upregulation of Bcl-xL has a long-term cytoprotective effect, meaning that the HGF/SF-
mediated protective machinery must be active within the cells before the cytotoxic 
damage occurs (Liu, 1999). As a universal mechanism, maintenance of HB and HCC 
cell survival by phosphorylation of Bad and upregulation of Bcl-xL would serve to ensure 
the transformation potential of HGF/SF, finally leading to cancer. Notably, it was 
reported that upregulation of Bcl-xL is not only mediated by Akt/PKB, but also by STAT3, 
thereby conferring resistance to apoptosis (Catlett-Falcone et al., 1999; Nielsen et al., 
1999). However, in the HB and HCC cell lines tested, HGF/SF was not capable of 
activating STAT3, suggesting that this pathway is not involved in HB and HCC 
cytoprotection. 
A third possibility would be that HGF/SF blocks the Bax translocation to the 
mitochondrial membrane, thereby inhibiting Bax pore formation and mitochondrial efflux 
of cytochrome c as previously reported (Liu, 1999; Nakagami et al., 2002). Bax is 
transcriptionally controlled by the tumor suppressor protein p53. High levels of Bax 
oligomerize at the outer mitochondrial membrane to induce the mitochondrial 
permeability transition (MPT), followed by cytochrome c efflux. Cells overexpressing 
both Bax and Bcl-2 family members show no signs of caspase activation and survive 
with significant amounts of cytochrome c in the cytoplasm (Rosse et al., 1998), 
suggesting that Bcl-2 family members control cell survival upstream and downstream of 
cytochrome c release (Hengartner, 1998; Hengartner, 2000). It would be interesting to 
investigate in more detail, whether HGF/SF is inducing one or more of the 
aforementioned effects in HB and HCC cells to further understand the molecular 
mechanisms leading to increased HB and HCC cell survival and thus tumor progression. 
 
In summary, the regulation and function of the PI3K/Akt pathway and the downstream 
signals of Akt/PKB in HB and HCC cells were investigated in this study. It was 
demonstrated that the PI3K/Akt pathway acts as a survival (anti-apoptotic) signal and 
that HGF/SF activates this pathway in HB and HCC cells. These data further suggest 
that HGF/SF serves as a survival factor acting through the PI3K/Akt pathway, thereby 
contributing to carcinogenesis. Interestingly, HGF/SF also protects MDCK cells from 
apoptosis induced by disruption of cell detachment, a process termed anoikis, which is 
consistent with the scattering phenotype induced by HGF/SF as discussed below 
(Frisch and Francis, 1994). 
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5.3 HGF/SF as a motility factor 
HGF/SF is particularly relevant to oncogenesis because not only does it enhance cell 
survival, but it also stimulates cell motility, invasive growth, and functions as a 
morphoregulatory agent. However, the knowledge about HGF/SF-induced signaling 
pathways involved in cell dissociation, motility, and invasion is restricted. Possible 
molecular mechanisms to explain the observed phenotypes were addressed in this 
study. To infiltrate the surrounding tissues, single motile tumor cells leave the tumor 
mass by breaking cell-cell contacts, known as tight and adherens junctions and break 
the basal lamina by activating MMPs (Friedl and Wolf, 2003; Kadono et al., 1998). Snail 
family proteins have emerged as major transcriptional repressors of E-cadherin 
expression, the prototype mediator of adherens junctions, and claudins, which are 
critically involved in tight junction formation (Ikenouchi et al., 2003). Here, three 
independent cellular systems were used to analyze the mechanisms underlying 
HGF/SF-mediated cell scattering and migration. When applying an shRNA approach, it 
was disclosed that HGF/SF requires Snail to repress E-cadherin expression and to 
induce cell scattering. Furthermore, the major parts of the HGF/SF-mediated signaling 
pathway leading to Snail expression and thus to cell scattering, migration and invasion 
have been unraveled. 
We demonstrate that HGF/SF induced a rapid and transient increase in both Snail 
mRNA and protein levels. Thereby, an inverse correlation between E-cadherin mRNA 
and Snail mRNA and protein levels was observed upon HGF/SF treatment. A similar 
correlation has been previously reported in HCC and in colon epithelial cells, where 
Snail expression and E-cadherin downregulation is associated with higher invasiveness 
(Boon et al., 2005; Sugimachi et al., 2003).  
In contrast, even after long-term treatment with HGF/SF we could not detect a clear 
downregulation of total E-cadherin protein in HepG2 cells. A long E-cadherin half-life 
and inconsistent mRNA and total protein levels have already been found in other cell 
systems (Maeda et al., 2005; Peinado et al., 2003; Strutz et al., 2002), suggesting a 
redistribution from the adherens sites rather than degradation (Shibamoto et al., 1994). 
Indeed, it has been previously reported that internalized E-cadherin is often recycled to 
sites of new cell-cell contacts (Gumbiner, 2000), or non-adhesion areas (Hiscox and 
Jiang, 1999). Furthermore, recent experiments with MDCK cells have demonstrated that 
the early events of HGF/SF-induced scattering do not involve a loss of E-cadherin 
protein and that a disruption of junctions by contractile forces induces cell scattering and 
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migration (de Rooij et al., 2005). Thus far, the shRNA knock-down experiments 
presented here clearly indicate that Snail is required for HGF/SF-mediated cell 
scattering. Hence, HGF/SF-induced Snail expression and Snail-mediated repression of 
E-cadherin function must be considered as an order of events. Furthermore, Snail might 
regulate other genes required for the scattering process, in conjunction with E-cadherin 
downregulation. In fact, Snail-mediated repression of a number of components of 
adherens, tight, and desmosomal junctions has been recently reported (Barrallo-Gimeno 
and Nieto, 2005). 
By employing a combination of specific inhibitors and biochemical analyses, the 
MAPK pathway was discovered to mediate HGF/SF-induced Snail upregulation and cell 
scattering. This finding was consistent with previous reports demonstrating that the 
MAPK pathway is required for HGF/SF-induced scattering of various epithelial cell types 
(Abella et al., 2005; Janda et al., 2002; Maina et al., 2001; Tanimura et al., 1998). 
Notably, the transcription factor Egr-1 appears to play a critical role in HGF/MAPK-
mediated induction of Snail expression and cell scattering. In fact, expression of a 
dominant-negative version of Egr-1 abolished HGF/SF-induced Snail expression. 
Unfortunately, forced expression of wildtype Egr-1 induces the expression of its own 
repressor Nab2, thus excluding a direct test whether Egr-1 alone is sufficient to induce 
Snail expression (Kumbrink et al., 2005). To circumvent this problem, expression of a 
mutant Egr-1, which is resistant to the Nab co-repressors (Al-Sarraj et al., 2005), 
resulted in a concentration-dependent upregulation of Snail promoter activity. These 
data suggest that upon induction by Egr-1, Snail binds to the Egr-1 promoter and 
represses its transcription. In fact, Snail has recently been shown to repress its own 
transcription (Peiro et al., 2006), thereby establishing a robust negative feedback loop 
that prevents sustained activation of Egr-1 and Snail. Hence, the stimulus-induced 
synthesis of Egr-1 and Snail is transient and might give a first signal to initiate a 
cascade leading to cell scattering. 
 
5.3.1 Regulation of Snail mRNA and protein levels  
The level of Snail in a cell is not only regulated at the transcriptional level, but also 
by protein stabilization. GSK-3β controls Snail’s subcellular localization and activity by 
phosphorylation of consensus sites. Importantly, the results from our experiments 
suggest additional regulatory steps in Snail expression. 
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5.3.1.1 Stabilization of Snail mRNA  
In our experiments we observed elevated mRNA levels of Snail upon exogenous 
expression of Snail protein (data not shown). At the same time, Snail promoter activity 
was not increased, suggesting a regulation of the Snail mRNA stability. Therefore, we 
performed an extensive search for known specific destructions sites, e.g. adenosine- 
and uridine-rich elements (ARE) (Espel, 2005) within the coding region of the mRNA, 
but did not detect any AREs within the Snail mRNA, suggesting other, yet unknown 
regulatory elements. 
It will be of particular importance to identify such elements as well as proteins able to 
bind to and to stabilize the Snail mRNA, since this could play a critical role in tumor 
progression. 
 
5.3.1.2 Alternative upregulation of translation 
Increased Snail protein levels were detected after HGF/SF treatment of cells 
expressing a GSK-3β-resistant form of Snail, suggesting that augmented Snail protein 
levels could also be due to enhanced translation of its mRNA. 
An alternative mode of translation initiation involves the recruitment of the 
translational initiation complex by an internal ribosome entry site (IRES). Translation by 
IRES was originally identified in picornavirus, but a number of cellular mRNAs have 
subsequently been found to contain IRES function, including basic FGF, VEGF, c-Myc, 
and HIF1-α (Lang et al., 2002; Stein et al., 1998; Stoneley et al., 2000; Vagner et al., 
1995). The cellular IRES have been shown to be involved in preservation of translational 
efficiency during cellular stress, e.g. hypoxia, serum deprivation, heat shock, or 
apoptosis when protein synthesis is reduced. Structural characteristics of IRES are a 
70% G + C-rich region in the 5’UTR of the mRNA and a 5’UTR length of at least 250 bp 
(Lang et al., 2002). 
When analyzing the originally published 5’UTR Snail sequence, we did not discover 
any characteristic IRES. However, an EST database search for extensions in the 5’UTR 
of Snail identified such a motif. This extended 5’UTR contains typical features of IRES, 
suggesting that Snail mRNA is a good candidate for being translated by alternative 
means and not being dependent on the cap-binding protein eIF4E, which is translation 
rate limiting. Further experiments, e.g. a dicistronic reporter assay, would be necessary 
to validate IRES-containing Snail mRNA and to check whether Snail translation is 
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increased under severe cellular conditions. This could be of particular importance since 
invading and metastasizing cells outlive several stressful environmental cues, such as 
lack of cell-cell and cell-matrix contacts, nutrients deprivation, and chemotherapeutic 
treatment. Increased translation of motility inducers like Snail could therefore help tumor 
cells in finding a new niche where they could rebuild the necessary microenvironment 
and reestablish the oxygen and nutrients’ supply. 
 
5.3.1.3 Increased Snail protein stability 
Elevated protein levels do not only result from increased translation, but also from 
protein stabilization. Stabilization of the Snail protein has already been extensively 
studied. As previously described, Snail sublocalization and stability is tightly regulated 
by GSK-3β activity (Bachelder et al., 2005; Zhou et al., 2004). However, this pathway is 
not involved in HGF/SF-mediated Snail protein stabilization (Figure 36), suggesting 
another regulatory mechanism. 
A mechanism that could contribute to the stabilization of Snail involves the protein 
kinase CKII (formerly known as casein kinase II). CKII is a ubiquitously expressed, 
pleitropic and constitutive-active serine/threonine kinase (reviewed in Faust and 
Montenarh, 2000). In most mammalian cells, the highly conserved holoenzyme is 
localized to both cytosol and nucleus. CKII consensus motifs (S/TxxE/D) are often found 
in close proximity to GSK-3β phosphorylation sites, e.g. in β-catenin and E-cadherin 
(Lickert et al., 2000; Serres et al., 2000). Interestingly, a potential CKII priming site 
exists in Snail, suggesting a role for CKII in Snail phosphorylation and increased 
degradation by the proteasome (see Figure 11). In fact, CKII has been found to 
associate with the proteasome complex, further suggesting that it targets or guides 
proteins to the proteasome and/or is degraded by the proteasomal pathway itself 
(Ludemann et al., 1993). 
CKII-mediated serine/threonine phosphorylation of β-catenin and E-cadherin leads 
to stabilization of adherens junctions, thereby promoting the maintenance of tissue 
homeostasis (Bek and Kemler, 2002; Lickert et al., 2000). Consequently, Snail would be 
repressed in this scenario. Inhibition of CKII could then lead to weakened β-catenin and 
E-cadherin proteins and stabilized Snail protein. Interestingly, CKII was also found to 
associate with Egr-1 and thereby decreasing its DNA binding capacity (Jain et al., 
1996). Thus, we hypothesize that CKII, as a central effector, could regulate additionally 
to GSK-3β the stability of Snail and of cell-cell adhesions in general. Additional 
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experiments are necessary to evaluate the role of CKII in transforming processes and 
whether HGF/SF has an influence on its activity. Besides heparin, thus far no other 
negative, external regulatory mechanism of the constitutive-active CKII is known. 
However, further experiments to determine the role of CKII in HGF/SF-triggered cell 
morphology changes and increase in cell survival will be required. 
 
5.3.1.4 Alternatives to Snail  
In addition to Snail, we also tested for two other known transcription repressors of 
E-cadherin, Slug and Twist, in various cancer cell lines. Slug is mainly produced in chick 
gastrula as well as in the neural crest of Xenopus and chick. It has also been shown to 
be essential for EMT in the mesoderm formation in chick (Nieto, 2002). The basic helix-
loop-helix (bHLH) transcription factor Twist was originally identified in the initiation of 
gastrulation in Drosophila (Thisse et al., 1987) and is also known to be a key inducer of 
metastasis in some tumors (Yang et al., 2004). In the qRT-PCR experiments performed, 
Slug and Twist mRNA was only detected in HEK293 cells, the breast cancer cell line 
MCF-7, and in the cervical HeLa cell line. In HepG2 cells, Slug and Twist mRNA levels 
were barely detectable. Upon HGF/SF treatment of the cell lines tested, only the 
HEK293 cells showed a slight increase in Twist and Slug mRNA levels. A similar finding 
correlating with our results was found in clinical data, where HCC were analyzed for 
E-cadherin, Snail and Slug mRNA levels. In tumors overexpressing Snail, a correlation 
between decreased E-cadherin levels and increased cell invasion was found (Sugimachi 
et al., 2003). However, Slug mRNA levels were neither linked to E-cadherin expression 
nor to tumor invasiveness, suggesting Snail to be the most prominent repressor of 
E-cadherin. Notably, we cannot rule out that in other cell systems or upon other stimuli, 
e.g. by FGF, TGF-β, and bone morphogenetic protein (BMP), Snail function is replaced 
by other transcriptional repressors. An increasing number of zinc-finger transcription 
factors, including SIP-1 and E12/E47, have been described as E-cadherin repressors 
and have also been implicated in the regulation of the EMT phenomena (Comijn et al., 
2001). Accordingly, for some breast cancer cell lines it has been shown that SIP-1 
mediates E-cadherin repression (Bindels et al., 2006). 
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5.3.2 HGF/SF, Egr-1, and Snail: a novel network 
Overall, the results pre-
sented here show that HGF/SF 
induces a transient expression 
of Snail, which is required for 
the induction of cell scattering. 
However, it is important to note 
that the forced expression of 
Snail by itself does not induce 
cell scattering in HepG2 or 
HEK293 cells (data not shown). 
This suggests that HGF/SF-
mediated scattering involves in 
addition to Egr-1/Snail a hitherto 
unknown pathway. Contrary to 
our results, Snail overex-
pression has previously been 
shown to induce EMT in other 
epithelial cell lines (Bachelder 
et al., 2005; Zhou et al., 2004). 
EMT is a process, where cell-
cell junctions are altered, 
epithelial polarity is lost, and the 
expression of mesenchymal 
markers, such as vimentin and 
smooth muscle actin, is gained 
(Thiery, 2002). Nonetheless, 
analysis of HGF/SF-treated 
HepG2 cells has not revealed 
any upregulation of mesen-
chymal markers (data not shown), suggesting that Snail-dependent scattering is distinct 
from Snail-induced EMT. 
 
Figure 47: Molecular mechanisms underlying HGF/SF-
induced cell scattering. 
Binding of HGF/SF to its receptor leads to 
autophosphorylation of c-Met and via adaptor molecules to 
the activation of the Ras/Raf/MAPK pathway. Activated 
MAPK then phosphorylates and activates immediate early 
transcription factors, such as c-Fos and Elk, which bind the 
Egr-1 promoter and induce Egr-1 gene expression. In turn, 
Egr-1 induces Snail gene expression. Newly synthesized 
Snail then binds the promoter of its target genes, including 
E-cadherin and claudin-3, thereby repressing their 
transcription. In addition, Snail represses transcription of 
the Egr-1 and Snail genes, thus mediating a negative 
feedback loop. GSK-3β provides a nuclear export signal by 
phosphorylating Snail on its phosphorylation consensus 
site II. Once in the cytoplasm, Snail is phosphorylated by 
GSK-3β on consensus site I, leading to its ubiquitination 
and proteasomal degradation, a process repressed by LiCl 
and MG132. 
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 Based on our findings and that of others’, it is conceivable that Snail plays a critical 
role in the early stages of cell scattering and EMT, by making tumor cells sensitive for 
further EMT stimuli, e.g. TGFβ, and setting the stage for invasive tumor progression 
(Huber et al., 2005). 
Our experimental results show for the first time a mechanism by which HGF/SF 
induces expression of the transcriptional repressor Snail and, with it, cell scattering, 
migration and invasion: stimulation of cells with HGF/SF leads to (i) activation of the 
MAPK signaling pathway, (ii) upregulation of Egr-1, which in turn (iii) induces Snail tran-
scription and, (iv) as a consequence results in the repression of Snail target genes, 
among them E-cadherin, claudins and Egr-1 itself (Figure 47). 
Further studies are warranted to characterize the molecular details of HGF/SF-
mediated signal transduction and Egr-1 function.  HGF/SF has been shown to induce 
the expression of a number of pro-angiogenic factors by activating Egr-1 (Day et al., 
2004; Recio and Merlino, 2003; Worden et al., 2005). In fact, induction of Egr-1 gene 
transcription is detected in many cell types in response to cytokines and mitogens 
(Gashler and Sukhatme, 1995; Kaufmann et al., 2001; Kaufmann and Thiel, 2002). 
Egr-1 activity has also been implicated in the development of several human cancer 
types, in particular, in human prostate cancer (Eid et al., 1998). Moreover, tumor 
progression in transgenic mouse models of prostate cancer is impaired when Egr-1 is 
lacking, and Egr-1 also appears to contribute to mouse skin carcinogenesis (Abdulkadir 
et al., 2001; Riggs et al., 2000).  
Interestingly, public accessible database “Oncomine” analysis of gene expression 
data sets from patients’ specimen has revealed a significant correlation between Snail, 
Egr-1, E-cadherin, claudins and c-Met and/or HGF/SF in glioblastoma multiforme 
(GBM), a highly invasive tumor, and in clear cell renal carcinoma (Grotegut et al., 2006). 
Consistent with these observations, in vivo inhibition of the c-Met pathway has resulted 
in a decrease of glioblastoma growth by 60% (Brockmann et al., 2003). 
 
5.4 Conclusions 
Although it is known that the majority of early-stage tumors are not life threatening, a 
small number of primary tumor cells will progress to metastatic tumors, which give rise 
to devastating and largely incurable disease. Tumor metastasis is comprised of multiple 
steps and thus tumor cells are required to express a variety of properties including 
altered adhesiveness, increased motility and invasive capacity to complete the 
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metastatic process (Hanahan and Weinberg, 
2000). Consistent with previous studies demon-
strating that HGF/SF is a potent promoter of the 
angiogenic and metastatic functions of tumor 
cells, this work shows that HGF/SF significantly 
enhanced cell survival, cell migration, and 
invasion capacity, this significantly contributes 
to a better understanding of the molecular 
mechanisms underlying the progression to 
tumor malignancy.  
 The work described here and that of others 
indicate that multiple pathways might be 
involved in the modulation of HGF/SF in tumor 
metastasis. First, it was found that HGF/SF 
caused higher resistance to chemotherapeutic 
agents and starvation. Second, HGF/SF-induced disturbance of tissue integrity through 
alterations of cell-cell and cell-matrix adhesion is a key event necessary for the 
progression of a variety of human carcinoma cells and the acquisition of an invasive 
phenotype. Third, HGF/SF-promoted cell motility is accompanied by activation of matrix 
metalloproteases (MMPs) and basement membrane breakdown. The functions of a 
family of structurally related MMPs and their inhibitors in tumor metastasis include not 
only a direct role in tumor invasion by facilitating extracellular matrix degradation, but 
also an important role in maintaining the tumor microenvironment, and thus promoting 
tumor progression (Curran and Murray, 1999). Fourth, HGF/SF induces angiogenesis at 
sites of metastasis, thereby promoting nutrient and oxygen supply essential for the 
tumor cells for colonizing new organs. However, further studies will be necessary to 
provide a comprehensive understanding of the role of HGF/SF in tumor progression and 
in metastatic processes. 
 c-Met inhibitor research stands at the doorstep of the oncology clinic. Neutralizing 
antibodies and the use of the HGF/SF antagonist NK4 to prevent ligand access to c-Met 
have successfully reversed cancer-associated phenotypes in vivo (Christensen et al., 
2005). New therapeutic strategies targeting the extracellular domain of c-Met such as 
soluble c-Met consisting of the entire extracellular region, called decoy Met, or the 
recombinant Sema domain that can inhibit ligand-dependent and -independent receptor 
Figure 48: Therapeutic strategies 
targeting the c-Met receptor. 
Soluble c-Met consisting of the entire 
extracellular domain (decoy Met) or 
recombinant Sema domain (rSema) 
inhibit HGF/SF binding and c-Met 
dimerization. Ligand-independent 
dimerization of c-Met is also blocked. 
PSI, plexin, semaphorin, and integrin 
domain (Zhang et al., 2004). 
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dimerization look highly promising (Figure 48)(Kong-Beltran et al., 2004; Michieli et al., 
2004). Because c-Met is inappropriately expressed in a large number of human cancers 
(see Table 2), the HGF/c-Met signaling pathway should be an exceptional target for 
anticancer strategies and therapies (Corso et al., 2005; Jiang et al., 2005). These will 
eventually be used routinely for the benefit of cancer patients. 
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β-TrCP β-transducin-repeat-containing protein 
ACE Angiotensin converting enzyme 
APAF Apoptotic peptidase activating factor 
APC Adenomatous polyposis coli 
ARE elements Adenosine- and uridine-rich elements 
bHLH Basic helix-loop-helix 
bp Basepair 
c-fos Cellular homologue to v-fos (FBJ murine 
osteosarcoma viral oncogene) 
ChIP Chromatin immunoprecipitation 
CHO Chinese hamster ovarian 
c-jun Cellular homologue to v-jun (avian 
sarcoma virus 17 oncogene) 
CK Casein kinase 
CPT Camptothecin 
Crk Chicken tumor virus no. 10 [CT10] 
regulator of kinase 
DAG Diacylglycerol 
DEPC Diethylpyrocarbonate 
DOC Sodium deoxycholate 
DPM Decays per minute 
DTT Dithiotreitol 
ECL Enhanced chemiluminescence 
EDTA Ethylendiamintetraacetate 
EGF Epidermal growth factor 
Egr-1 Early growth response factor 1 
EGTA Ethylene glycol-bis(2-aminoethyl)-N, N, 
N’, N’-tetraacetic acid 
eIF4E Eukaryontic translation initiation factor 4E 
EMSA Electrophoretic mobility shift assay 
EMT Epithelial-mesenchymal transition 
ERK Extracellular signal-regulated kinase 
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EST Expressed sequence tag 
FAK Focal adhesion kinase 
FAP Familial adenomatous polyposis 
FCS Fetal calf serum 
FS-Fb-c Me Human foreskin fibroblasts-conditioned 
medium 
Gab1 Grb2-associated binder-1 
GAS Interferon-γ-activated sequence/ site 
GEF Guanine nucleotide exchange factor 
Grb2 Growth factor receptor binding protein 2 
GSK-3β Glycogen synthase kinase 3β 
GTP Guanosin triphosphate 
HB Hepatoblastoma 
HBV Hepatitis B virus 
HCC Hepatocellular carcinoma 
HCV Hepatitis C virus  
HEK293 Human embryonal kidney 293 cells 
HEPES N-(2-Hydroxyethyl)-piperazin-N’-2-
ethansulfonic acid 
HGF/SF Hepatocyte growth factor/scatter factor 
hRPL Human ribosomal protein L19 
IFN Interferon 
IL Interleukin 
ILK Integrin-linked kinase 
InsP3 Inositol-1,4,5-triphosphate 
IRES Internal ribosome entry site 
IRF9 Interferon regulatory factor 9 
ISGF3 Interferon-stimulated gene factor 3 
Jak Just another kinase 
Lef Lymphoid enhancer factor-1 
LOH Loss of heterozygosity 
LOI Loss of imprinting 
LOXL Lysyl oxydase-like protein 
MAPK Mitogen-activated protein kinase 
MDCK Madin-Darby canine kidney 
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MDR-1 multidrug resistance gene 
MEK MAPK kinase 
MMP Matrix metalloproteinase 
MPT Mitochondrial permeability transition 
MTA3 Metastasis-associated protein-3 
mTOR Mammilian target of rapamycin 
Na3VO4 Sodium orthovanadate 
Nab NGF1A-binding protein 
NaF Sodium fluoride 
NCAM Neural cell adhesion molecule 
p130CAS p130Crk-associated substrate 
PAGE polyacrylamide gel electrophoresis 
PAI-1 Plasminogen activator inhibitor-1 
PAK1 p21-activated kinase-1 
PBS Phosphate buffered saline 
PD98059 2’-amino-3’-methoxyflavone 
PDGF Platelet-derived growth factor 
PH pleckstrin homology 
PI3K Phosphatidylinositol 3-kinase 
PIP2 Phosphatidylinositol-4,5-diphosphate 
PKB Protein kinase B 
PKC Protein kinase C 
PLC Phospholipase C 
PMSF Phenyl methyl sulfonyl fluoride 
PTEN Phosphatase and tensin homolog deleted 
on chromosome ten 
qRT-PCR Quantitative real time detection reverse 
transcription polymerase chain reaction 
Raf Homologue to v-raf (murine sarcoma viral 
oncogene) 
Ras Homologue to v-ras (rat sarcoma viral 
oncogene) 
ROS Reactive oxygen species 
RT Room temperature 
RTK Receptor tyrosine kinase 
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SCF Stem cell factor 
SDS Sodiumdodecylsulfate 
SDS-PAGE SDS polyacrylamide gel electrophoresis 
SH2 Src homology 2 
Shp2 SH2 domain containing tyrosine 
phosphatase 
shRNA Small hairpin RNA 
SIE Serum-inducible element 
SIP-1 Smad-interacting protein-1 
SOS Son of sevenless 
Src Homologue to v-src (sarcoma viral 
oncogene) 
STAT Signal transducer and activator of 
transcription 
TBS Tris-buffered saline 
TCA Trichloroacetic acid 
TCF T cell factor 
TEMED N, N, N’, N’-Tetramethylethylenediamine 
TGF Transforming growth factor 
TNF Tumor necrosis factor 
TKB Tyrosine kinase binding 
Tris Tris(hydroxymethyl)aminomethan 
Tween 20 Polyoxyethylensorbitanmonolaureate 
VEGF Vascular endothelial growth factor 
Wn Wortmannin 
ZO-1 Zonula occludens (ZO)-1 
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